# EDGAR Filing Document

**Accession Number:** 0001702744
**File Stem:** 0001702744-26-000006
**Filing Date:** 2026-1
**Character Count:** 131901
**Document Hash:** 7536d12f1914b1b3d1be92b09c6c4de0
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001702744-26-000006.hdr.sgml**: 20260108

**ACCESSION NUMBER**: 0001702744-26-000006

**CONFORMED SUBMISSION TYPE**: 10-Q

**PUBLIC DOCUMENT COUNT**: 65

**CONFORMED PERIOD OF REPORT**: 20251129

**FILED AS OF DATE**: 20260108

**DATE AS OF CHANGE**: 20260108

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Simply Good Foods Co
- **CENTRAL INDEX KEY:** 0001702744
- **STANDARD INDUSTRIAL CLASSIFICATION:** FOOD & KINDRED PRODUCTS [2000]
- **ORGANIZATION NAME:** 04 Manufacturing
- **EIN:** 821038121
- **FISCAL YEAR END:** 0826

**FILING VALUES:**
- **FORM TYPE:** 10-Q
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38115
- **FILM NUMBER:** 26517516

**BUSINESS ADDRESS:**
- **STREET 1:** 1225 17TH STREET
- **STREET 2:** SUITE 1000
- **CITY:** DENVER
- **STATE:** CO
- **ZIP:** 80202
- **BUSINESS PHONE:** 303-633-2840

**MAIL ADDRESS:**
- **STREET 1:** 1225 17TH STREET
- **STREET 2:** SUITE 1000
- **CITY:** DENVER
- **STATE:** CO
- **ZIP:** 80202

?xml version='1.0' encoding='ASCII'? atk-20251129

**&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

_______________________________________________________

**FORM 10-Q** 

_______________________________________________________

---

| | |
|:---|:---|
| **(Mark One)** | |
| ☒ | **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |

---

For the quarterly period ended November 29, 2025

---

| | |
|:---|:---|
| **OR** | **OR** |
| &nbsp;&nbsp;&nbsp;&nbsp;o | **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934** |
| **For the transition period from ________ to ________** | **For the transition period from ________ to ________** |

---

**Commission File Number: 001-38115** 

___________________________________________________________________________________________________________

**The Simply Good Foods Company** 

(Exact name of registrant as specified in its charter)

![SGF Logo_Primary (1).jpg](atk-20251129_g1.jpg)

___________________________________________________________________________________________________________

---

| | |
|:---|:---|
| **Delaware** | **82-1038121** |
| (State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) |

---

**1225 17th Street, Suite 1000** 

**Denver, CO 80202** 

(Address of principal executive offices and zip code)

**(303) 633-2840**

(Registrant's telephone number, including area code)

___________________________________________________________________________________________________________

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| Title of each class | Trading symbol | Name of each exchange on which registered |
| Common Stock, par value $0.01 per share | SMPL | Nasdaq |

---

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Date File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

---

| | | | |
|:---|:---|:---|:---|
| Large accelerated filer | ☒ | Accelerated filer | ☐ |
| Non-accelerated filer | ☐ | Smaller reporting company | ☐ |
| | | Emerging growth company | ☐ |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of January 6, 2026, there were 92,575,255 shares of common stock, par value $0.01 per share, issued and outstanding.

------

**THE SIMPLY GOOD FOODS COMPANY AND SUBSIDIARIES**

**FORM 10-Q**

**FOR THE QUARTER ENDED NOVEMBER 29, 2025**

**INDEX**

---

| | | |
|:---|:---|:---|
| | | **<u>Page</u>** |
| **<u>[PART I. Financial Information](#i49be39206c734f3a8b58002db19dcadf_10)</u>** | **<u>[PART I. Financial Information](#i49be39206c734f3a8b58002db19dcadf_10)</u>** | **<u>[PART I. Financial Information](#i49be39206c734f3a8b58002db19dcadf_10)</u>** |
| <u>[Item 1](#i49be39206c734f3a8b58002db19dcadf_13)</u>. | <u>[Financial Statements (Unaudited)](#i49be39206c734f3a8b58002db19dcadf_13)</u> | <u>[3](#i49be39206c734f3a8b58002db19dcadf_13)</u> |
|  | <u>[Consolidated Balance Sheets](#i49be39206c734f3a8b58002db19dcadf_16)</u> | <u>[3](#i49be39206c734f3a8b58002db19dcadf_16)</u> |
|  | <u>[Consolidated Statements of Operations and Comprehensive Income](#i49be39206c734f3a8b58002db19dcadf_22)</u> | <u>[4](#i49be39206c734f3a8b58002db19dcadf_22)</u> |
|  | <u>[Consolidated Statements of Cash Flows](#i49be39206c734f3a8b58002db19dcadf_25)</u> | <u>[5](#i49be39206c734f3a8b58002db19dcadf_25)</u> |
|  | <u>[Consolidated Statements of Stockholders' Equity](#i49be39206c734f3a8b58002db19dcadf_28)</u> | <u>[7](#i49be39206c734f3a8b58002db19dcadf_28)</u> |
|  | <u>[Notes to Unaudited Consolidated Financial Statements](#i49be39206c734f3a8b58002db19dcadf_31)</u> | <u>[8](#i49be39206c734f3a8b58002db19dcadf_31)</u> |
| <u>[Item 2](#i49be39206c734f3a8b58002db19dcadf_88)</u>. | <u>[Management's Discussion and Analysis of Financial Condition and Results of Operations](#i49be39206c734f3a8b58002db19dcadf_88)</u> | <u>[19](#i49be39206c734f3a8b58002db19dcadf_88)</u> |
| <u>[Item 3](#i49be39206c734f3a8b58002db19dcadf_118)</u>. | <u>[Quantitative and Qualitative Disclosures about Market Risk](#i49be39206c734f3a8b58002db19dcadf_118)</u> | <u>[27](#i49be39206c734f3a8b58002db19dcadf_118)</u> |
| <u>[Item 4](#i49be39206c734f3a8b58002db19dcadf_121)</u>. | <u>[Controls and Procedures](#i49be39206c734f3a8b58002db19dcadf_121)</u> | <u>[27](#i49be39206c734f3a8b58002db19dcadf_121)</u> |
| **<u>[PART II. Other Information](#i49be39206c734f3a8b58002db19dcadf_124)</u>** | **<u>[PART II. Other Information](#i49be39206c734f3a8b58002db19dcadf_124)</u>** | **<u>[PART II. Other Information](#i49be39206c734f3a8b58002db19dcadf_124)</u>** |
| <u>[Item 1](#i49be39206c734f3a8b58002db19dcadf_127)</u>. | <u>[Legal Proceedings](#i49be39206c734f3a8b58002db19dcadf_127)</u> | <u>[28](#i49be39206c734f3a8b58002db19dcadf_127)</u> |
| <u>[Item 1A](#i49be39206c734f3a8b58002db19dcadf_130)</u>. | <u>[Risk Factors](#i49be39206c734f3a8b58002db19dcadf_130)</u> | <u>[28](#i49be39206c734f3a8b58002db19dcadf_130)</u> |
| <u>[Item 2](#i49be39206c734f3a8b58002db19dcadf_133)</u>. | <u>[Unregistered Sales of Equity Securities and Use of Proceeds](#i49be39206c734f3a8b58002db19dcadf_133)</u> | <u>[29](#i49be39206c734f3a8b58002db19dcadf_133)</u> |
| <u>[Item 3](#i49be39206c734f3a8b58002db19dcadf_136)</u>. | <u>[Defaults Upon Senior Securities](#i49be39206c734f3a8b58002db19dcadf_136)</u> | <u>[30](#i49be39206c734f3a8b58002db19dcadf_136)</u> |
| <u>[Item 4](#i49be39206c734f3a8b58002db19dcadf_139)</u>. | <u>[Mine Safety Disclosures](#i49be39206c734f3a8b58002db19dcadf_139)</u> | <u>[30](#i49be39206c734f3a8b58002db19dcadf_139)</u> |
| <u>[Item 5](#i49be39206c734f3a8b58002db19dcadf_142)</u>. | <u>[Other Information](#i49be39206c734f3a8b58002db19dcadf_142)</u> | <u>[30](#i49be39206c734f3a8b58002db19dcadf_142)</u> |
| <u>[Item 6](#i49be39206c734f3a8b58002db19dcadf_145)</u>. | <u>[Exhibits](#i49be39206c734f3a8b58002db19dcadf_145)</u> | <u>[31](#i49be39206c734f3a8b58002db19dcadf_145)</u> |
|  | <u>[Signatures](#i49be39206c734f3a8b58002db19dcadf_148)</u> | <u>[32](#i49be39206c734f3a8b58002db19dcadf_148)</u> |

---

------

**PART I. Financial Information**

**Item 1. Financial Statements (Unaudited)**

**The Simply Good Foods Company and Subsidiaries**

**Consolidated Balance Sheets**

*(Unaudited, dollars in thousands, except share and per share data)*

---

| | | |
|:---|:---|:---|
| | November 29, 2025 | August 30, 2025 |
| Assets |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;Cash | $194051 | $98468 |
| &nbsp;&nbsp;&nbsp;Accounts receivable, net | 129178 | 164978 |
| &nbsp;&nbsp;&nbsp;Inventories | 181148 | 167217 |
| &nbsp;&nbsp;&nbsp;Prepaid expenses | 4398 | 7209 |
| &nbsp;&nbsp;&nbsp;Other current assets | 5064 | 15812 |
| &nbsp;&nbsp;&nbsp;Total current assets | 513839 | 453684 |
| Long-term assets: |  |  |
| &nbsp;&nbsp;&nbsp;Property and equipment, net | 38851 | 39738 |
| &nbsp;&nbsp;&nbsp;Intangible assets, net | 1257642 | 1261603 |
| &nbsp;&nbsp;&nbsp;Goodwill | 589974 | 589974 |
| &nbsp;&nbsp;&nbsp;Other long-term assets | 50321 | 51046 |
| &nbsp;&nbsp;&nbsp;Total assets | $2450627 | $2396045 |
| Liabilities and stockholders' equity |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Accounts payable | $75486 | $78298 |
| &nbsp;&nbsp;&nbsp;Accrued interest | 66 | 44 |
| &nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | 27069 | 46219 |
| &nbsp;&nbsp;&nbsp;Total current liabilities | 102621 | 124561 |
| Long-term liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;Long-term debt, less current maturities | 396744 | 249066 |
| &nbsp;&nbsp;&nbsp;Deferred income taxes | 169627 | 166091 |
| &nbsp;&nbsp;&nbsp;Other long-term liabilities | 47519 | 49494 |
| &nbsp;&nbsp;&nbsp;Total liabilities | 716511 | 589212 |
| See commitments and contingencies (Note 9) |  |  |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;Preferred stock, $0.01 par value, 100,000,000 shares authorized, none issued |  |  |
| &nbsp;&nbsp;&nbsp;Common stock, $0.01 par value, 600,000,000 shares authorized, 103,940,255 and 103,688,071 shares issued at November 29, 2025, and August 30, 2025, respectively | 1039 | 1037 |
| &nbsp;&nbsp;&nbsp;Treasury stock, 8,941,085 shares and 3,957,571 shares at cost at November 29, 2025, and August 30, 2025, respectively | (230026) | (129337) |
| &nbsp;&nbsp;&nbsp;Additional paid-in-capital | 1349610 | 1346687 |
| &nbsp;&nbsp;&nbsp;Retained earnings | 616148 | 590879 |
| &nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | (2655) | (2433) |
| &nbsp;&nbsp;&nbsp;Total stockholders' equity | 1734116 | 1806833 |
| Total liabilities and stockholders' equity | $2450627 | $2396045 |

---

*See accompanying notes to the unaudited consolidated financial statements.*

------

<u>[Table](#i49be39206c734f3a8b58002db19dcadf_7)[of Contents](#i49be39206c734f3a8b58002db19dcadf_7)</u>

**The Simply Good Foods Company and Subsidiaries**

**Consolidated Statements of Operations and Comprehensive Income**

*(Unaudited, dollars in thousands, except share and per share data)*

---

| | | |
|:---|:---|:---|
| | Thirteen Weeks Ended | Thirteen Weeks Ended |
| | November 29, 2025 | November 30, 2024 |
| Net sales | $340198 | $341268 |
| Cost of goods sold | 230298 | 210782 |
| Gross profit | 109900 | 130486 |
| Operating expenses: |  |  |
| &nbsp;&nbsp;&nbsp;Selling and marketing | 29677 | 32994 |
| &nbsp;&nbsp;&nbsp;General and administrative | 38006 | 38064 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 4633 | 4160 |
| &nbsp;&nbsp;&nbsp;Business transaction costs |  | 643 |
| Total operating expenses | 72316 | 75861 |
| Income from operations | 37584 | 54625 |
| Other income (expense): |  |  |
| &nbsp;&nbsp;&nbsp;Interest income | 499 | 776 |
| &nbsp;&nbsp;&nbsp;Interest expense | (4286) | (7861) |
| &nbsp;&nbsp;&nbsp;(Loss) gain on foreign currency transactions | (57) | 120 |
| &nbsp;&nbsp;&nbsp;Other income | 76 | 15 |
| Total other income (expense) | (3768) | (6950) |
| Income before income taxes | 33816 | 47675 |
| Income tax expense | 8547 | 9553 |
| Net income | $25269 | $38122 |
| Other comprehensive income: |  |  |
| &nbsp;&nbsp;&nbsp;Foreign currency translation, net of reclassification adjustments | (222) | (387) |
| Comprehensive income | $25047 | $37735 |
| Earnings per share from net income: |  |  |
| &nbsp;&nbsp;&nbsp;Basic | $0.26 | $0.38 |
| &nbsp;&nbsp;&nbsp;Diluted | $0.26 | $0.38 |
| Weighted average shares outstanding: |  |  |
| &nbsp;&nbsp;&nbsp;Basic | 98749340 | 100394693 |
| &nbsp;&nbsp;&nbsp;Diluted | 99051004 | 101479603 |

---

*See accompanying notes to the unaudited consolidated financial statements.*

------

<u>[Table](#i49be39206c734f3a8b58002db19dcadf_7)[of Contents](#i49be39206c734f3a8b58002db19dcadf_7)</u>

**The Simply Good Foods Company and Subsidiaries**

**Consolidated Statements of Cash Flows**

*(Unaudited, dollars in thousands)*

---

| | | |
|:---|:---|:---|
| | Thirteen Weeks Ended | Thirteen Weeks Ended |
| | November 29, 2025 | November 30, 2024 |
| Operating activities |  |  |
| Net income | $25269 | $38122 |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 6205 | 5047 |
| &nbsp;&nbsp;&nbsp;Amortization of deferred financing costs and debt discount | 150 | 506 |
| &nbsp;&nbsp;&nbsp;Stock compensation expense | 3083 | 3844 |
| &nbsp;&nbsp;&nbsp;Estimated credit losses | 20 | 750 |
| &nbsp;&nbsp;&nbsp;Unrealized loss (gain) on foreign currency transactions | 57 | (120) |
| &nbsp;&nbsp;&nbsp;Deferred income taxes | 3536 | 3374 |
| &nbsp;&nbsp;&nbsp;Amortization of operating lease right-of-use asset | 1480 | 1678 |
| &nbsp;&nbsp;&nbsp;Other | (279) | (402) |
| &nbsp;&nbsp;&nbsp;Changes in operating assets and liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts receivable, net | 35768 | 67 |
| &nbsp;&nbsp;&nbsp;&nbsp;Inventories | (13605) | (13157) |
| &nbsp;&nbsp;&nbsp;&nbsp;Prepaid expenses | 2672 | (958) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other current assets | 10794 | (1396) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accounts payable | (2012) | 319 |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued interest | 22 | (189) |
| &nbsp;&nbsp;&nbsp;&nbsp;Accrued expenses and other current liabilities | (22288) | (3707) |
| &nbsp;&nbsp;&nbsp;&nbsp;Other assets and liabilities | (778) | (1757) |
| Net cash provided by operating activities | 50094 | 32021 |
| Investing activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Purchases of property and equipment | (2096) | (307) |
| &nbsp;&nbsp;&nbsp;&nbsp;Investments in intangible and other assets |  | (362) |
| Net cash used in investing activities | (2096) | (669) |
| Financing activities |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from option exercises | 1056 | 9984 |
| &nbsp;&nbsp;&nbsp;&nbsp;Tax payments related to issuance of restricted stock units and performance stock units | (1214) | (2315) |
| &nbsp;&nbsp;&nbsp;&nbsp;Repurchase of common stock | (99638) |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Principal payments of long-term debt |  | (50000) |
| &nbsp;&nbsp;&nbsp;&nbsp;Proceeds from issuance of long-term debt | 150000 |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Deferred financing costs | (2585) |  |
| Net cash provided by (used in) financing activities | 47619 | (42331) |
| Cash and cash equivalents |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net increase (decrease) in cash | 95617 | (10979) |
| &nbsp;&nbsp;&nbsp;&nbsp;Effect of exchange rate on cash | (34) | 208 |
| &nbsp;&nbsp;&nbsp;&nbsp;Cash at beginning of period | 98468 | 132530 |
| Cash and cash equivalents at end of period | $194051 | $121759 |

---

------

<u>[Table](#i49be39206c734f3a8b58002db19dcadf_7)[of Contents](#i49be39206c734f3a8b58002db19dcadf_7)</u>

---

| | | |
|:---|:---|:---|
| | Thirteen Weeks Ended | Thirteen Weeks Ended |
| | November 29, 2025 | November 30, 2024 |
| Supplemental disclosures of cash flow information |  |  |
| &nbsp;&nbsp;Cash paid for interest | $4114 | $7544 |
| &nbsp;&nbsp;Cash paid for taxes | $29 | $395 |
| Non-cash investing and financing transactions |  |  |
| &nbsp;&nbsp;&nbsp;Non-cash credits for repayment of note receivable | $49 | $200 |
| &nbsp;&nbsp;&nbsp;Non-cash additions to property and equipment | $42 | $59 |
| &nbsp;&nbsp;&nbsp;Non-cash additions to intangible assets | $— | $64 |

---

*See accompanying notes to the unaudited consolidated financial statements.*

------

<u>[Table](#i49be39206c734f3a8b58002db19dcadf_7)[of Contents](#i49be39206c734f3a8b58002db19dcadf_7)</u>

**The Simply Good Foods Company and Subsidiaries**

**Consolidated Statements of Stockholders' Equity**

*(Unaudited, dollars in thousands, except share data)*

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | Common Stock | Common Stock | Treasury Stock | Treasury Stock | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Total |
| | Shares | Amount | Shares | Amount | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Total |
| Balance at August 30, 2025 | 103688071 | $1037 | 3957571 | $(129337) | $1346687 | $590879 | $(2433) | $1806833 |
| &nbsp;&nbsp;&nbsp;Net income |  |  |  |  |  | 25269 |  | 25269 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation |  |  |  |  | 3083 |  |  | 3083 |
| &nbsp;&nbsp;&nbsp;Foreign currency translation adjustments |  |  |  |  |  |  | (222) | (222) |
| &nbsp;&nbsp;&nbsp;Repurchase of common stock |  |  | 4983514 | (100689) |  |  |  | (100689) |
| &nbsp;&nbsp;&nbsp;Shares issued upon vesting of restricted stock units and performance stock units | 164184 | 1 |  |  | (1215) |  |  | (1214) |
| &nbsp;&nbsp;&nbsp;Exercise of options to purchase common stock | 88000 | 1 |  |  | 1055 |  |  | 1056 |
| Balance at November 29, 2025 | 103940255 | $1039 | 8941085 | $(230026) | $1349610 | $616148 | $(2655) | $1734116 |

---

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | Common Stock | Common Stock | Treasury Stock | Treasury Stock | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Total |
| | Shares | Amount | Shares | Amount | Additional Paid-In Capital | Retained Earnings | Accumulated Other Comprehensive Loss | Total |
| Balance at August 31, 2024 | 102515315 | $1025 | 2365100 | $(78451) | $1319686 | $487265 | $(2039) | $1727486 |
| &nbsp;&nbsp;&nbsp;Net income |  |  |  |  |  | 38122 |  | 38122 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation |  |  |  |  | 3654 |  |  | 3654 |
| &nbsp;&nbsp;&nbsp;Foreign currency translation adjustments |  |  |  |  |  |  | (387) | (387) |
| &nbsp;&nbsp;&nbsp;Shares issued upon vesting of restricted stock units and performance stock units | 164093 | 2 |  |  | (2317) |  |  | (2315) |
| &nbsp;&nbsp;&nbsp;Exercise of options to purchase common stock | 713751 | 7 |  |  | 9977 |  |  | 9984 |
| Balance at November 30, 2024 | 103393159 | $1034 | 2365100 | $(78451) | $1331000 | $525387 | $(2426) | $1776544 |

---

*See accompanying notes to the unaudited consolidated financial statements.*

------

<u>[Table](#i49be39206c734f3a8b58002db19dcadf_7)[of Contents](#i49be39206c734f3a8b58002db19dcadf_7)</u>

**Notes to Unaudited Consolidated Financial Statements**

*(Unaudited, dollars in thousands, except for share and per share data)*

**1. Nature of Operations and Principles of Consolidation**

***Description of Business***

The Simply Good Foods Company ("Simply Good Foods" or the "Company"), headquartered in Denver, Colorado, is a consumer packaged food and beverage company with ambitious goals to raise the bar on what food can be with trusted brands and innovative nutritious snacking products. Within our portfolio of trusted brands (Quest, Atkins, and OWYN), we offer a wide variety of nutritional snacks and beverages, including high protein chips, bars, ready-to-drink (RTD) shakes, and powders, and low sugar, low carb sweets and baked goods. We are a leader of the nutritious snacking movement, poised to expand our healthy lifestyle platform through innovation-driven organic growth and external investment opportunities.

Our nutritious snacking platform consists of brands that specialize in providing products for consumers that follow certain nutritional philosophies and health-and-wellness trends: Quest for consumers seeking a variety of protein-rich foods and beverages that also limit sugars and simple carbohydrates, Atkins for those following a low-carbohydrate lifestyle or seeking to manage weight or blood sugar levels, and OWYN for consumers seeking protein-rich beverages that are plant-based and tested for the top nine allergens that also limit sugars and simple carbohydrates. We distribute our products in major retail channels, primarily in North America, including grocery, club, and mass merchandise, as well as through e-commerce, convenience, specialty, and other channels. Our portfolio of nutritious snacking brands gives us a strong platform with which to introduce new products, expand distribution, and attract new consumers to our products.

The common stock of Simply Good Foods is listed on the Nasdaq Capital Market under the symbol "SMPL."

***Unaudited Interim Consolidated Financial Statements***

The unaudited interim consolidated financial statements include the accounts of Simply Good Foods and its wholly-owned subsidiaries. All intercompany accounts and transactions have been eliminated. Unless the context otherwise requires, "we," "us," "our" and the "Company" refer to Simply Good Foods and its subsidiaries. In context, "Quest" may also refer to the Quest brand, "Atkins" may also refer to the Atkins brand, and "OWYN" may also refer to the OWYN brand. Atkins, Atkins Endulge, Quest, OWYN, and the Simply Good logo are either registered trademarks or trademarks of the Company's wholly owned subsidiary Simply Good Foods USA, Inc. or one of its affiliates in the United States and elsewhere. All rights are reserved.

The Company maintains its accounting records on a 52/53-week fiscal year, ending on the last Saturday in August.

The interim consolidated financial statements and related notes of the Company and its subsidiaries are unaudited. The unaudited interim consolidated financial statements have been prepared in accordance with U.S. Generally Accepted Accounting Principles ("GAAP") and the rules and regulations of the Securities and Exchange Commission (the "SEC"). The unaudited interim consolidated financial statements reflect all adjustments and disclosures which are, in the Company's opinion, necessary for a fair presentation of the results of operations, financial position and cash flows for the indicated periods. All such adjustments were of a normal and recurring nature unless otherwise disclosed. The year-end balance sheet data was derived from the audited financial statements and, in accordance with the instructions to Form 10-Q, certain information and footnote disclosures required by GAAP have been condensed or omitted. The results reported in these unaudited interim consolidated financial statements are not necessarily indicative of the results that may be reported for the entire fiscal year and should be read in conjunction with the Company's consolidated financial statements for the fiscal year ended August 30, 2025, included in the Company's Annual Report on Form 10-K ("Annual Report") filed with the SEC on October 28, 2025.

------

<u>[Table](#i49be39206c734f3a8b58002db19dcadf_7)[of Contents](#i49be39206c734f3a8b58002db19dcadf_7)</u>

**2. Summary of Significant Accounting Policies**

Refer to Note 2, *Summary of Significant Accounting Policies*, to the consolidated financial statements included in the Annual Report for a description of significant accounting policies.

***Recently Issued and Adopted Accounting Pronouncements***

*Recently Issued Accounting Pronouncements Not Yet Adopted*

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740), Improvements to Income Tax Disclosures ("ASU 2023-09"), which updates disclosures required in the footnotes to the financial statements to further aid investors in understanding how to analyze income tax reporting. The amendments are effective for fiscal years beginning after December 15, 2024. Early adoption is permitted for annual financial statements that have not yet been issued or made available. The amendments should be applied on a prospective basis, however, retrospective application is permitted. The Company is currently evaluating the provisions of the amendments and the effect on its future consolidated financial statements.

In November 2024, the FASB issued ASU No. 2024-03, Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses ("ASU 2024-03"), which will improve the disclosures about a public business entity's expenses and address requests from investors for more detailed information about the types of expenses in commonly presented expense captions such as cost of sales, SG&A, and R&D. The amendments are effective for fiscal years beginning after December 15, 2026, and for interim periods within fiscal years beginning after December 15, 2027. Early adoption is permitted for annual financial statements that have not yet been issued or made available. The amendments should be applied on either (1) prospectively to financial statements issued for reporting periods after the effective date, or (2) retrospectively to any or all prior periods presented in the financial statements. The Company is currently evaluating the provisions of the amendments and the effect on its future consolidated financial statements.

In September 2025, the FASB issued ASU No. 2025-06, Intangibles - Goodwill and Other - Internal Use Software ("ASU 2025-06"), which will improve disclosures surrounding internal-use software and the timing of capitalization when companies use the incremental and iterative development method. The amendments are effective for fiscal years beginning after December 15, 2027, and for interim periods within those fiscal years. Early adoption is permitted. The amendments should be applied through (1) a prospective transition approach, (2) a retrospective transition approach, or (3) a modified transition approach that is based on the status of the project and whether software costs were capitalized before the date of adoption. The Company is currently evaluating the provisions of the amendments and the effect on its future consolidated financial statements.

No other new accounting pronouncement issued or effective during the fiscal year had or is expected to have a material effect on the Company's consolidated financial statements.

**3. Revenue Recognition**

Revenue from transactions with external customers for each of the Company's products would be impracticable to disclose and management does not view its business by product line. The following is a summary of revenue disaggregated by geographic area and brands:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Thirteen Weeks Ended | Thirteen Weeks Ended | Thirteen Weeks Ended | Thirteen Weeks Ended |
| *(In thousands)* | November 29, 2025 | November 29, 2025 | November 30, 2024 | November 30, 2024 |
| North America <sup>(1)</sup> |  |  |  |  |
| &nbsp;&nbsp;Atkins | $| 90270 | $| 108168 |
| &nbsp;&nbsp;Quest | 210343 | 210343 | 191937 | 191937 |
| &nbsp;&nbsp;OWYN | 31182 | 31182 | 32254 | 32254 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total North America | 331795 | 331795 | 332359 | 332359 |
| International | 8403 | 8403 | 8909 | 8909 |
| &nbsp;&nbsp;Total net sales | $| 340198 | $| 341268 |
| <sup>(1)</sup> The North America geographic area consists of net sales substantially related to the United States and there is no individual foreign country to which more than 10% of the Company's net sales are attributed or that is otherwise deemed individually material. | <sup>(1)</sup> The North America geographic area consists of net sales substantially related to the United States and there is no individual foreign country to which more than 10% of the Company's net sales are attributed or that is otherwise deemed individually material. | <sup>(1)</sup> The North America geographic area consists of net sales substantially related to the United States and there is no individual foreign country to which more than 10% of the Company's net sales are attributed or that is otherwise deemed individually material. | <sup>(1)</sup> The North America geographic area consists of net sales substantially related to the United States and there is no individual foreign country to which more than 10% of the Company's net sales are attributed or that is otherwise deemed individually material. | <sup>(1)</sup> The North America geographic area consists of net sales substantially related to the United States and there is no individual foreign country to which more than 10% of the Company's net sales are attributed or that is otherwise deemed individually material. |

---

Charges related to credit losses on accounts receivable from transactions with external customers were immaterial for the thirteen weeks ended November 29, 2025, and $0.8 million for the thirteen weeks ended November 30, 2024. As of both November 29, 2025, and August 30, 2025, the allowance for credit losses related to accounts receivable were $0.9 million.

------

<u>[Table](#i49be39206c734f3a8b58002db19dcadf_7)[of Contents](#i49be39206c734f3a8b58002db19dcadf_7)</u>

**4. Goodwill and Intangibles**

As of November 29, 2025, and August 30, 2025, *Goodwill* in the Consolidated Balance Sheets was $590.0 million. There were no impairment charges related to goodwill during the thirteen weeks ended November 29, 2025, or since the inception of the Company.

&nbsp;&nbsp;&nbsp;&nbsp;

*Intangible assets, net* in the Consolidated Balance Sheets consists of the following:

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | | November 29, 2025 | November 29, 2025 | November 29, 2025 |
| *(In thousands)* | Useful life | Useful life | Gross carrying amount | Accumulated amortization | Net carrying<br>amount |
| Intangible assets with indefinite life: |  |  |  |  |  |
| &nbsp;&nbsp;Brands and trademarks | Indefinite life | Indefinite life | $1142000 | $— | $1142000 |
| Intangible assets with finite lives: |  |  |  |  |  |
| &nbsp;&nbsp;Customer relationships | 15 years | 15 years | 194500 | 81380 | 113120 |
| &nbsp;&nbsp;Licensing agreements | 10 years | 10 years | 16072 | 14757 | 1315 |
| &nbsp;&nbsp;Proprietary recipes and formulas | 7 years | 7 years | 7000 | 7000 |  |
| &nbsp;&nbsp;Software and website development costs | 3 | 5 years | 6641 | 5434 | 1207 |
|  |  |  | $1366213 | $108571 | $1257642 |

---

---

| | | | | | |
|:---|:---|:---|:---|:---|:---|
| | | | August 30, 2025 | August 30, 2025 | August 30, 2025 |
| *(In thousands)* | Useful life | Useful life | Gross carrying amount | Accumulated amortization | Net carrying<br>amount |
| Intangible assets with indefinite life: |  |  |  |  |  |
| &nbsp;&nbsp;Brands and trademarks | Indefinite life | Indefinite life | $1142000 | $— | $1142000 |
| Intangible assets with finite lives: |  |  |  |  |  |
| &nbsp;&nbsp;Customer relationships | 15 years | 15 years | 194500 | 78138 | 116362 |
| &nbsp;&nbsp;Licensing agreements | 10 years | 10 years | 16072 | 14319 | 1753 |
| &nbsp;&nbsp;Proprietary recipes and formulas | 7 years | 7 years | 7000 | 7000 |  |
| &nbsp;&nbsp;Software and website development costs | 3 | 5 years | 6641 | 5153 | 1488 |
|  |  |  | $1366213 | $104610 | $1261603 |

---

Changes in *Intangible assets, net* during the thirteen weeks ended November 29, 2025, were primarily related to recurring amortization expense. Amortization expense related to intangible assets was $4.0 million for the thirteen weeks ended November 29, 2025, and $3.7 million for the thirteen weeks ended November 30, 2024. There were no impairment charges related to its indefinite-lived or finite-lived intangible assets during the thirteen weeks ended November 29, 2025, and November 30, 2024.

We believe the estimates and assumptions utilized in our impairment assessments are reasonable and are comparable to those that would be used by other marketplace participants. However, actual events and results could differ substantially from those utilized in our initial valuations. Significant declines of future revenue projections or changes of other assumptions used in estimating fair values versus those utilized at the time of the initial valuations could result in impairment charges that could materially affect the consolidated financial statements.

Estimated future amortization for each of the next five fiscal years and thereafter is as follows:

---

| | |
|:---|:---|
| *(In thousands)* | Amortization |
| Remainder of 2026 | $11638 |
| 2027 | 13575 |
| 2028 | 12967 |
| 2029 | 12967 |
| 2030 | 12967 |
| 2031 and thereafter | 51528 |
| Total | $115642 |

---

------

<u>[Table](#i49be39206c734f3a8b58002db19dcadf_7)[of Contents](#i49be39206c734f3a8b58002db19dcadf_7)</u>

**5. Long-Term Debt and Line of Credit** 

On July 7, 2017, the Company (through certain of its subsidiaries) entered into a credit agreement with Barclays Bank PLC and other parties (as amended to date, the "Credit Agreement"). The Credit Agreement at that time provided for (i) a term facility of $200.0 million ("Term Facility") with a seven-year maturity and (ii) a revolving credit facility of up to $75.0 million (the "Revolving Credit Facility") with a five-year maturity. Substantially concurrent with the consummation of the business combination which formed the Company between Conyers Park Acquisition Corp. and NCP-ATK Holdings, Inc. on July 7, 2017, the full $200.0 million of the Term Facility (the "Term Loan") was drawn.

On November 7, 2019, the Company entered into a second amendment (the "Incremental Facility Amendment") to the Credit Agreement to increase the principal borrowed on the Term Facility by $460.0 million. The Term Facility together with the incremental borrowing make up the Initial Term Loans (as defined in the Incremental Facility Amendment). The Incremental Facility Amendment was executed to partially finance the acquisition of Quest Nutrition, LLC on November 7, 2019. No amounts under the Term Facility were repaid as a result of the execution of the Incremental Facility Amendment.

Effective as of December 16, 2021, the Company entered into a third amendment (the "Extension Amendment") to the Credit Agreement. The Extension Amendment provided for an extension of the stated maturity date of the Revolving Commitments and Revolving Loans (each as defined in the Credit Agreement) from July 7, 2022, to the earlier of (i) 91 days prior to the then-effective maturity date of the Initial Term Loans and (ii) December 16, 2026.

On January 21, 2022, the Company entered into the "2022 Repricing Amendment" to the Credit Agreement. The 2022 Repricing Amendment, among other things, (i) reduced the interest rate per annum applicable to the Initial Term Loans outstanding under the Credit Agreement immediately prior to the effective date of the 2022 Repricing Amendment, (ii) reset the prepayment premium for the existing Initial Term Loans to apply to Repricing Transactions (as defined in the Credit Agreement) that occur within six months after the effective date of the 2022 Repricing Amendment, and (iii) implemented SOFR and related replacement provisions for LIBOR.

On April 25, 2023, the Company entered into the "2023 Repricing Amendment" to the Credit Agreement. The 2023 Repricing Amendment, (i) reduced the interest rate per annum applicable to the Initial Term Loans outstanding under the Credit Agreement immediately prior to April 25, 2023, and (ii) provided for an extension of the maturity date of the Initial Term Loans from July 7, 2024, to March 17, 2027.

On June 13, 2024, the Company entered into a sixth amendment (the "2024 Incremental Facility Amendment") to the Credit Agreement to increase the principal borrowed on the Term Facility by $250.0 million. The terms of the incremental borrowing are the same as the terms of the outstanding borrowings under the Term Facility. The 2024 Incremental Facility Amendment was executed to partially finance the OWYN Acquisition. No amounts under the Term Facility were repaid as a result of the execution of the 2024 Incremental Facility Amendment.

On January 31, 2025, the Company entered into a seventh amendment (the "2025 Repricing Amendment") to the Credit Agreement to reduce the interest rate per annum applicable to the Initial Term Loans outstanding under the Credit Agreement immediately prior to the effective date of the 2025 Repricing Amendment.

On November 19, 2025, the Company entered into an eighth amendment (the "2026 Incremental Facility Amendment") to the Credit Agreement to increase the principal borrowed on the Term Facility by $150.0 million and provided for an extension of the maturity date from March 17, 2027 to March 17, 2030. The 2026 Incremental Facility Amendment also provided for an extension of the stated maturity date of the Revolving Commitments and Revolving Loans (each as defined in the Credit Agreement) from December 16, 2026, to the earlier of (i) 91 days prior to the then-effective maturity date of the Term Facility and (ii) December 16, 2029. The terms of the incremental borrowing are substantially the same as the terms of the outstanding borrowings under the Term Facility. No amounts of the Term Facility were repaid as a result of the execution of the 2026 Incremental Facility Amendment.

Effective as of the 2026 Incremental Facility Amendment, the interest rate per annum for the Initial Term Loans is based on either:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i.A base rate equaling the higher of (a) the "prime rate," (b) the federal funds effective rate plus 0.50%, or (c) the Adjusted Term SOFR Rate (as defined in the Credit Agreement) applicable for an interest period of one month plus 1.00% plus (x) 1.00% margin for the Term Loan or (y) 1.00% margin for the Revolving Credit Facility; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii.SOFR, subject to a floor of 0.00%, plus (x) 2.00% margin for the Term Loan or (y) 2.00% margin for the Revolving Credit Facility.

In connection with the closing of the 2026 Incremental Facility Amendment, the Company expensed $2.5 million of non-deferrable third-party costs through *General and administrative* within the Consolidated Statements of Operations and Comprehensive Income and capitalized $2.6 million of upfront lender fees (original issue discount) and third-party financing costs.

The Simply Good Foods Company is not a borrower under the Credit Agreement and has not provided a guarantee of the Credit Agreement. Simply Good Foods USA, Inc., is the administrative borrower and certain other subsidiary holding companies are co-borrowers under the Credit Agreement. Each of the Company's domestic subsidiaries that are not a named borrower under the Credit Agreement has

------

<u>[Table](#i49be39206c734f3a8b58002db19dcadf_7)[of Contents](#i49be39206c734f3a8b58002db19dcadf_7)</u>

provided a guarantee on a secured basis. As security for the payment or performance of the debt under the Credit Agreement, the borrowers and the guarantors have pledged certain equity interests in their respective subsidiaries and granted the lenders a security interest in substantially all of their domestic assets. All guarantors other than Quest Nutrition, LLC and Only What You Need, Inc. are holding companies with no assets other than their investments in their respective subsidiaries.

The Credit Agreement contains certain financial and other covenants that limit the Company's ability to, among other things, incur and/or undertake asset sales and other dispositions, liens, indebtedness, certain acquisitions and investments, consolidations, mergers, reorganizations and other fundamental changes, payment of dividends and other distributions to equity and warrant holders, and prepayments of material subordinated debt, in each case, subject to customary exceptions materially consistent with credit facilities of such type and size. The Revolving Credit Facility has a maximum total net leverage ratio equal to or less than 6.00:1.00 contingent on credit extensions in excess of 30% of the total amount of commitments available under the Revolving Credit Facility. Any failure to comply with the restrictions of the credit facilities may result in an event of default. The Company was in compliance with all covenants as of November 29, 2025, and August 30, 2025, respectively.

Long-term debt consists of the following:

---

| | | |
|:---|:---|:---|
| *(In thousands)* | November 29, 2025 | August 30, 2025 |
| Term Facility (effective rate of 5.9% at November 29, 2025) | $400000 | $250000 |
| Less: Deferred financing fees | 3256 | 934 |
| Long-term debt, net of deferred financing fees | $396744 | $249066 |

---

The Company is not required to make principal payments on the Term Facility over the twelve months following the period ended November 29, 2025. The outstanding balance of the Term Facility is due upon its maturity in March 2030.

As of November 29, 2025, the Company had letters of credit in the amount of $0.8 million outstanding. These letters of credit offset against the $75.0 million availability of the Revolving Credit Facility and exist to support two of the Company's leased buildings. No amounts were drawn against these letters of credit as of November 29, 2025.

The Company utilizes market approaches to estimate the fair value of certain outstanding borrowings by discounting anticipated future cash flows derived from the contractual terms of the obligations and observable market interest and foreign exchange rates. The Company carries debt at historical cost and discloses fair value. As of November 29, 2025, and August 30, 2025, the book value of the Company's debt approximated fair value. The estimated fair value of the Term Loan is valued based on observable inputs and classified as Level 2 in the fair value hierarchy.

**6. Fair Value of Financial Instruments** 

Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. To increase the comparability of fair value measurements, a three-tier fair value hierarchy, which prioritizes the inputs used in the valuation methodologies, is used:

Level 1 – Valuations based on quoted prices for identical assets and liabilities in active markets.

Level 2 – Valuations based on observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data.

Level 3 – Valuations based on unobservable inputs reflecting the Company's own assumptions, consistent with reasonably available assumptions made by other market participants. These valuations require significant judgment.

Components of the balance sheet such as accounts receivable, cash and cash equivalents, and others approximate fair value as of November 29, 2025.

------

<u>[**Table of Contents**](#i49be39206c734f3a8b58002db19dcadf_7)</u>

**7. Income Taxes**

The tax expense and the effective tax rate resulting from operations were as follows:

---

| | | |
|:---|:---|:---|
| | Thirteen Weeks Ended | Thirteen Weeks Ended |
| *(In thousands)* | November 29, 2025 | November 30, 2024 |
| Income before income taxes | $33816 | $47675 |
| Provision for income taxes | $8547 | $9553 |
| Effective tax rate | 25.3% | 20.0% |

---

The effective tax rate for the thirteen weeks ended November 29, 2025 was 5.3% higher than the effective tax rate for the thirteen weeks ended November 30, 2024, which was primarily due to the absence of excess tax benefits from stock option exercises recognized in the prior-year period.

**8. Leases**

The Company generally leases office space and distribution centers in the United States through operating lease agreements. As of the thirteen weeks ended November 29, 2025, the Company had no finance lease agreements. Our leases have remaining lease terms up to 7 years and most include an option to renew for additional terms.

The Company's lease costs recognized in the Consolidated Statement of Operations consist of the following:

---

| | | | |
|:---|:---|:---|:---|
| | | Thirteen Weeks Ended | Thirteen Weeks Ended |
| *(In thousands)* | Statements of Operations Caption | November 29, 2025 | November 30, 2024 |
| Operating lease cost: |  |  |  |
| &nbsp;&nbsp;&nbsp;Lease cost | *Cost of goods sold and General and administrative* | $2304 | $2209 |
| &nbsp;&nbsp;Variable lease cost <sup>(1)</sup> | *Cost of goods sold and General and administrative* | 1274 | 858 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total operating lease cost |  | 3578 | 3067 |
| Total lease cost |  | $3578 | $3067 |
| <sup>(1)</sup> Variable lease cost primarily consists of common area maintenance, such as cleaning and repairs. | <sup>(1)</sup> Variable lease cost primarily consists of common area maintenance, such as cleaning and repairs. | <sup>(1)</sup> Variable lease cost primarily consists of common area maintenance, such as cleaning and repairs. | <sup>(1)</sup> Variable lease cost primarily consists of common area maintenance, such as cleaning and repairs. |

---

The right-of-use assets and corresponding liabilities related to operating are as follows:

---

| | | | |
|:---|:---|:---|:---|
| *(In thousands)* | Balance Sheets Caption | November 29, 2025 | August 30, 2025 |
| Assets |  |  |  |
| Operating lease right-of-use assets | *Other long-term assets* | $42638 | $44118 |
| &nbsp;&nbsp;&nbsp;Total lease assets |  | $42638 | $44118 |
| Liabilities |  |  |  |
| Current: |  |  |  |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities | *Accrued expenses and other current liabilities* | $6823 | $5867 |
| Long-term: |  |  |  |
| &nbsp;&nbsp;&nbsp;Operating lease liabilities | *Other long-term liabilities* | 47519 | 49494 |
| &nbsp;&nbsp;&nbsp;&nbsp;Total lease liabilities |  | $54342 | $55361 |

---

------

<u>[**Table of Contents**](#i49be39206c734f3a8b58002db19dcadf_7)</u>

Future maturities of lease liabilities as of November 29, 2025, were as follows:

---

| | |
|:---|:---|
| *(In thousands)* | Operating Leases |
| Fiscal year ending: |  |
| Remainder of 2026 | $7206 |
| 2027 | 10927 |
| 2028 | 10388 |
| 2029 | 10438 |
| 2030 | 10549 |
| Thereafter | 16146 |
| Total lease payments | 65654 |
| Less: Interest | (11312) |
| Present value of lease liabilities | $54342 |

---

The weighted-average remaining lease terms and weighted-average discount rates for operating leases were as follows:

---

| | | |
|:---|:---|:---|
| | November 29, 2025 | August 30, 2025 |
| Weighted-average remaining lease term (in years) |  |  |
| &nbsp;&nbsp;Operating leases | 6.06 | 6.31 |
| Weighted-average discount rate |  |  |
| &nbsp;&nbsp;Operating leases | 6.0% | 6.0% |

---

Supplemental and other information related to operating leases was as follows:

---

| | | |
|:---|:---|:---|
| | Thirteen Weeks Ended | Thirteen Weeks Ended |
| *(In thousands)* | November 29, 2025 | November 30, 2024 |
| Cash paid for amounts included in the measurement of lease liabilities |  |  |
| &nbsp;&nbsp;&nbsp;Operating cash flows from operating leases | $2566 | $2510 |

---

**9. Commitments and Contingencies**

***Litigation***

The Company is a party to certain litigation and claims that are considered normal to the operations of the business. From time to time, the Company has been and may again become involved in legal proceedings arising in the ordinary course of business. The Company is not presently a party to any litigation that it believes to be material, and the Company is not aware of any pending or threatened litigation against it that its management believes could have a material adverse effect on its business, operating results, financial condition or cash flows.

***Other***

The Company enters into endorsement contracts with certain celebrity figures and social media influencers to promote and endorse the Quest, Atkins, and OWYN brands and product lines. These contracts contain endorsement fees, which are expensed ratably over the life of the contract, and performance fees, that are recognized at the time of achievement. Based on the terms of contracts in place and achievement of performance conditions as of November 29, 2025, the Company will be required to make payments of $0.1 million over the next year.

------

<u>[**Table of Contents**](#i49be39206c734f3a8b58002db19dcadf_7)</u>

**10. Stockholders' Equity**

***Stock Repurchase Program***

The Company adopted a $50.0 million stock repurchase program on November 13, 2018. On April 13, 2022, October 21, 2022, and October 21, 2025, the Company announced that its Board of Directors had approved the addition of $50.0 million, $50.0 million, and $150.0 million, respectively, to its stock repurchase program, resulting in authorized stock repurchases of up to an aggregate of $300.0 million. Under the stock repurchase program, the Company may repurchase shares from time to time in the open market or in privately negotiated transactions. The stock repurchase program does not obligate the Company to acquire any specific number of shares or acquire shares over any specific period of time. The stock repurchase program may be suspended or discontinued at any time by the Company and does not have an expiration date.

During the thirteen weeks ended November 29, 2025, the Company repurchased 4,983,514 shares of common stock at an average price of $19.99 per share, inclusive of commissions and exclusive of accrued excise tax. The U.S. Inflation Reduction Act of 2022 requires a 1% excise tax on the net amount of share repurchases. The Company did not repurchase any shares of common stock during the thirteen weeks ended November 30, 2024. As of November 29, 2025, approximately $71.0 million remained available under the stock repurchase program.

In January 2026, the Company's Board of Directors approved a $200 million increase to its existing stock repurchase program. Subsequent to the thirteen weeks ended November 29, 2025, and through January 6, 2026, the Company repurchased 2,430,028 shares of common stock at an average price of $19.34 per share, inclusive of commissions and exclusive of accrued excise tax. As of January 6, 2026, the Company has approximately $224.0 million available under its revised stock repurchase program.

**11. Earnings Per Share**

Basic earnings or loss per share is based on the weighted average number of common shares issued and outstanding. In computing diluted earnings per share, basic earnings per share is adjusted for the assumed issuance of all potentially dilutive securities, including the Company's employee stock options and non-vested stock units.

In periods in which the Company has a net loss, diluted loss per share is based on the weighted average number of common shares issued and outstanding as the effect of including common stock equivalents outstanding would be anti-dilutive.

The following table reconciles the numerators and denominators used in the computations of both basic and diluted earnings per share:

---

| | | |
|:---|:---|:---|
| | Thirteen Weeks Ended | Thirteen Weeks Ended |
| *(In thousands, except per share data)* | November 29, 2025 | November 30, 2024 |
| Basic earnings per share computation: |  |  |
| &nbsp;&nbsp;Numerator: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income available to common stockholders | $25269 | $38122 |
| &nbsp;&nbsp;Denominator: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted average common shares outstanding - basic | 98749340 | 100394693 |
| &nbsp;&nbsp;&nbsp;Basic earnings per share from net income | $0.26 | $0.38 |
| Diluted earnings per share computation: |  |  |
| &nbsp;&nbsp;Numerator: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Net income available for common stockholders | $25269 | $38122 |
| &nbsp;&nbsp;&nbsp;&nbsp;Numerator for diluted earnings per share | $25269 | $38122 |
| &nbsp;&nbsp;Denominator: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted average common shares outstanding - basic | 98749340 | 100394693 |
| &nbsp;&nbsp;&nbsp;&nbsp;Employee stock options | 210380 | 910180 |
| &nbsp;&nbsp;&nbsp;&nbsp;Non-vested stock units | 91284 | 174730 |
| &nbsp;&nbsp;&nbsp;&nbsp;Weighted average common shares - diluted | 99051004 | 101479603 |
| &nbsp;&nbsp;Diluted earnings per share from net income | $0.26 | $0.38 |

---

------

<u>[**Table of Contents**](#i49be39206c734f3a8b58002db19dcadf_7)</u>

Diluted earnings per share calculations for the thirteen weeks ended November 29, 2025, November 30, 2024, excluded 0.9 million and 0.7 million shares of common stock issuable upon exercise of stock options that would have been anti-dilutive.

Diluted earnings per share calculations for the thirteen weeks ended November 29, 2025, and November 30, 2024, excluded 0.4 million and an immaterial number of non-vested stock units that would have been anti-dilutive.

**12. Omnibus Incentive Plan**

Stock-based compensation includes stock options, restricted stock units, performance stock unit awards, and stock appreciation rights, which are awarded to employees, directors, and consultants of the Company. Stock-based compensation expense is recognized on a straight-line basis over the requisite service period of the award based on their grant date fair value. Stock-based compensation expense is included within *General and administrative* expense, which is the same financial statement caption where recipient's other compensation is reported.

The Company recorded stock-based compensation expense of $3.1 million and $3.8 million in the thirteen weeks ended November 29, 2025, and November 30, 2024, respectively.

***Stock Options***

The following table summarizes stock option activity for the thirteen weeks ended November 29, 2025:

---

| | | | |
|:---|:---|:---|:---|
| | Shares underlying options | Weighted average<br>exercise price | Weighted average remaining contractual life (years) |
| Outstanding as of August 30, 2025 | 1476243 | $25.44 | 4.61 |
| &nbsp;&nbsp;&nbsp;Granted |  |  |  |
| &nbsp;&nbsp;&nbsp;Exercised | (88000) | 12.00 |  |
| &nbsp;&nbsp;&nbsp;Forfeited | (928) | 38.61 |  |
| Outstanding as of November 29, 2025 | 1387315 | $26.28 | 4.49 |
| Vested and expected to vest as of November 29, 2025 | 1387315 | $26.28 | 4.49 |
| Exercisable as of November 29, 2025 | 1197402 | $24.62 | 3.98 |

---

As of November 29, 2025, the Company had $0.8 million of total unrecognized compensation cost related to stock options that will be recognized over a weighted average period of 0.7 years. During the thirteen weeks ended November 29, 2025, and November 30, 2024, the Company received $1.1 million and $10.0 million in cash from stock option exercises, respectively.

***Restricted Stock Units***

The following table summarizes restricted stock unit activity for the thirteen weeks ended November 29, 2025:

---

| | | |
|:---|:---|:---|
| | Units | Weighted average<br>grant-date fair value |
| Non-vested as of August 30, 2025 | 639015 | $36.14 |
| &nbsp;&nbsp;&nbsp;Granted | 451449 | 20.50 |
| &nbsp;&nbsp;&nbsp;Vested | (167460) | 36.22 |
| &nbsp;&nbsp;&nbsp;Forfeited | (14715) | 35.32 |
| Non-vested as of November 29, 2025 | 908289 | $28.37 |

---

As of November 29, 2025, the Company had $20.5 million of total unrecognized compensation cost related to restricted stock units that will be recognized over a weighted average period of 2.2 years.

***Performance Stock Units***

During the thirteen weeks ended November 29, 2025, the Board of Directors granted performance stock units under the Company's 2017 Omnibus Incentive Plan. The number of shares issuable as a result of grants of performance stock units is determined based on market-based criteria, performance-based criteria, or a combination of market-based criteria and performance-based criteria. The number of shares may be increased or decreased based on the results of these metrics in accordance with the terms established at the date of grant.

------

<u>[**Table of Contents**](#i49be39206c734f3a8b58002db19dcadf_7)</u>

For market-based criteria awards, the Company's relative total shareholder return, or relative TSR, is measured for the Company and each company in the Russell 3000 Food & Beverage index using the immediately preceding 30-day average share price at the beginning and end of the applicable three-year performance period. The percentile rank of the Company's TSR relative to that of the peer group determines the percent of the target award earned, ranging between 0% and 200%. The related compensation expense is recognized ratably over the term regardless of whether or not the market condition is satisfied, provided the requisite service is rendered. These units are valued using a Monte Carlo simulation.

For Company financial performance-based criteria awards, we estimate the probability that the Company's internally established performance criteria will be achieved at each reporting period and adjust compensation expense accordingly. The performance metrics achieved determines the percent of the target award earned, ranging between 0% and 200%. These units are valued using the closing market price of the Company's common stock on the date of grant.

For market-based criteria and Company financial performance-based criteria awards, the Company's TSR within the peer group and the performance metrics achieved determines the percent of the target award earned, ranging between 0% and 275%. We estimate the probability that the performance criteria will be achieved at each reporting period and adjust compensation expense accordingly. Should the performance-based criteria not be probable of being achieved, the compensation expense for the value of the award incorporating the market-based criteria is recognized ratably over the term, provided the requisite service is rendered. These units are valued using a Monte Carlo simulation.

The following table summarizes performance stock unit activity for the thirteen weeks ended November 29, 2025:

---

| | | |
|:---|:---|:---|
| | Units | Weighted average<br>grant-date fair value |
| Non-vested as of August 30, 2025 | 278193 | $52.66 |
| &nbsp;&nbsp;&nbsp;Granted | 290348 | 23.92 |
| &nbsp;&nbsp;&nbsp;Vested | (56651) | 62.55 |
| &nbsp;&nbsp;&nbsp;Forfeited | (17977) | 42.84 |
| Non-vested as of November 29, 2025 | 493913 | $34.99 |

---

Performance stock units are generally granted to employees as a part of the annual grant in November of the associated fiscal year, although the Board of Directors reserves the right to administer mid-year grants from time to time as they see fit. The fair value of each performance stock unit grant with a market-based TSR component is estimated on the date of grant using a Monte-Carlo simulation based on the following assumptions presented below which are associated with each year's annual grant:

---

| | | |
|:---|:---|:---|
| | Thirteen Weeks Ended<br>November 29, 2025 | Thirteen Weeks Ended<br>November 30, 2024 |
| Expected volatility | 29.96% | 31.38% |
| Expected dividend yield | —% | —% |
| Expected performance term | 2.93 | 2.93 |
| Risk-free rate of return | 3.54% | 4.14% |
| Fair value | $22.22 | $54.41 |

---

As of November 29, 2025, the Company had $10.0 million of total unrecognized compensation cost related to performance stock units that will be recognized over an expected weighted average period of 2.4 years.

***Stock Appreciation Rights***

Stock appreciation rights ("SARs") permit the holder to participate in the appreciation of the Company's common stock price and are awarded to non-employee consultants of the Company. The SARs settle in shares of its common stock once the applicable vesting criteria have been met. The SARs outstanding as of November 29, 2025, cliff vested two years from the date of grant and must be exercised within five years from the date of grant.

------

<u>[**Table of Contents**](#i49be39206c734f3a8b58002db19dcadf_7)</u>

The following table summarizes SARs activity for the thirteen weeks ended November 29, 2025:

---

| | | |
|:---|:---|:---|
| | Shares underlying SARs | Weighted average<br>exercise price |
| Outstanding as of August 30, 2025 | 150000 | $37.67 |
| &nbsp;&nbsp;Granted |  |  |
| &nbsp;&nbsp;Exercised |  |  |
| &nbsp;&nbsp;Forfeited |  |  |
| Outstanding as of November 29, 2025 | 150000 | $37.67 |
| Vested as of November 29, 2025 | 150000 | $37.67 |
| Exercisable as of November 29, 2025 | 150000 | $37.67 |

---

The SARs outstanding as of the thirteen weeks ended November 29, 2025, are liability-classified; therefore, the related stock-based compensation expense is based on the vesting provisions and the fair value of the awards.

**13. Segment Information**

The Company substantially completed its efforts to fully integrate its operations and organizational structure after the OWYN Acquisition. The Company aligned the nature of its production processes and methods used to distribute products to customers and its organizational structure to support entity-wide business functions across brands, products, customers, and geographic regions. As a result, as of the thirteen weeks ended November 29, 2025, the Company determined its operations are organized into one consolidated operating segment and reportable segment, represented by the Company's consolidated financial statements. Previously, as of November 30, 2024, the Company's operations were organized into two operating segments, Quest and Atkins, and OWYN, which were aggregated into one reportable segment due to similar financial, economic and operating characteristics.

The Chief Operating Decision Maker ("CODM") is the Chief Executive Officer ("CEO"). The CODM regularly reviews consolidated segment performance including net sales, significant expenses, net income, Adjusted EBITDA, budget to actual variance analysis, as well as other key metrics. The CODM uses net income as the measure of profitability to assess segment performance and allocate resources. The accounting policies of the segment are the same as those described in Note 2, Summary of Significant Accounting Policies.

The following table summarizes our segment net sales, significant expenses, and net income for the thirteen weeks ended November 29, 2025, and November 30, 2024:

---

| | | |
|:---|:---|:---|
| | Thirteen Weeks Ended | Thirteen Weeks Ended |
| | November 29, 2025 | November 30, 2024 |
| Net sales | $340198 | $341268 |
| Cost of goods sold | 230298 | 210782 |
| Operating expenses: |  |  |
| &nbsp;&nbsp;&nbsp;Selling and marketing | 29677 | 32994 |
| &nbsp;&nbsp;&nbsp;General and administrative | 38006 | 38064 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 4633 | 4160 |
| &nbsp;&nbsp;&nbsp;Business transaction costs |  | 643 |
| Other income (expense) | (3768) | (6950) |
| Income tax expense | 8547 | 9553 |
| Net income | $25269 | $38122 |

---

------

<u>[Table](#i49be39206c734f3a8b58002db19dcadf_7)[of Contents](#i49be39206c734f3a8b58002db19dcadf_7)</u>

**Item 2. &nbsp;&nbsp;&nbsp;&nbsp;Management's Discussion and Analysis of Financial Condition and Results of Operations** 

*This Quarterly Report on Form 10-Q (this "Report") contains forward-looking statements. When used anywhere in this Report, the words "expect," "believe," "anticipate," "estimate," "intend," "plan" and similar expressions are intended to identify forward-looking statements. These statements relate to future events or our future financial or operational performance and involve known and unknown risks, uncertainties and other factors that could cause our actual results, levels of activity, performance or achievements to differ materially from those expressed or implied by these forward-looking statements. These statements include, but are not limited to, our expectations regarding our supply chain, including but not limited to, raw materials and logistics costs, the effect of price increases, inflationary pressure on us and our contract manufacturers, changes in taxes, tariffs, duties, governmental laws and regulations, our growth, our competitive position, and the unforeseen business disruptions or other effects due to current global geopolitical tension. We disclaim any undertaking to publicly update or revise any forward-looking statements contained herein to reflect any change in our expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based, except as required by applicable law. These statements reflect our current views with respect to future events and are based on assumptions subject to risks and uncertainties. Such risks and uncertainties include those related to our ability to sell our products.*

*The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our consolidated financial statements and related notes included in our Annual Report on Form 10-K for the fiscal year ended August 30, 2025, ("Annual Report") and our unaudited consolidated financial statements and the related notes appearing elsewhere in this Report. In addition to historical information, the following discussion contains forward-looking statements, including, but not limited to, statements regarding the Company's expectation for future performance, liquidity and capital resources that involve risks, uncertainties and assumptions that could cause actual results to differ materially from the Company's expectations. The Company's actual results may differ materially from those contained in or implied by any forward-looking statements. Factors that could cause such differences include those identified in Item 1A. "Risk Factors" of our Annual Report and this Report. The Company assumes no obligation to update any of these forward-looking statements.*

*Unless the context requires otherwise in this Report, the terms "we," "us," "our," the "Company" and "Simply Good Foods" refer to The Simply Good Foods Company and its subsidiaries. In context, "Quest" may also refer to the Quest brand, "Atkins" may also refer to the Atkins brand, and "OWYN" may also refer to the OWYN brand. Atkins, Quest, OWYN, and the Simply Good logo are either registered trademarks or trademarks of the Company's wholly owned subsidiary Simply Good Foods USA, Inc. or one of its affiliates in the United States and elsewhere. All rights are reserved.*

**Overview**

The Simply Good Foods Company, headquartered in Denver, Colorado, is a consumer packaged food and beverage company with ambitious goals to raise the bar on what food can be with trusted brands and innovative nutritious snacking products. Within our portfolio of trusted brands (Quest, Atkins, and OWYN), we offer a wide variety of nutritional snacks and beverages, including high protein chips, bars, ready-to-drink (RTD) shakes, and powders, and low sugar, low carb sweets and baked goods. We are a leader of the nutritious snacking movement, poised to expand our healthy lifestyle platform through innovation-driven organic growth and external investment opportunities.

Our nutritious snacking platform consists of brands that specialize in providing products for consumers that follow certain nutritional philosophies and health-and-wellness trends: Quest for consumers seeking a variety of protein-rich foods and beverages that also limit sugars and simple carbohydrates, Atkins for those following a low-carbohydrate lifestyle or seeking to manage weight or blood sugar levels, and OWYN for consumers seeking protein-rich beverages that are plant-based and tested for the top nine allergens that also limit sugars and simple carbohydrates. We distribute our products in major retail channels, primarily in North America, including grocery, club, and mass merchandise, and through e-commerce, convenience, specialty, and other channels. Our portfolio of nutritious snacking brands gives us a strong platform with which to introduce new products, expand distribution, and attract new consumers to our products.

The Simply Good Foods Company ("Simply Good Foods") was formed in March 2017, to acquire NCP-ATK Holdings, Inc. ("Atkins"), which was completed in July 2017. As part of Simply Good Foods' strategy to become an industry leading snacking platform, we acquired Quest Nutrition, LLC ("Quest") in November 2019 and we acquired Only What You Need, Inc in June 2024. We refer to the acquisition of Quest Nutrition, LLC as the "Quest Acquisition" and the acquisition of Only What You Need, Inc. as the "OWYN Acquisition".

**Business Trends**

During the thirteen weeks ended November 29, 2025, our results of operations were primarily driven by continued distribution-related declines for Atkins and modest declines for OWYN, which were partially offset by Quest volume-driven growth. In recent periods, retail distribution for the Atkins brand has been under pressure. The Atkins brand has had, and continues to have, a large retail presence on-shelf, which is being reduced in the current fiscal year and could be reduced in future periods. In response, during the current fiscal year, we are taking actions to bolster the highest performing Atkins products and simultaneously working with retailers to replace lower performing Atkins products with higher performing Quest and OWYN products.

The Company's gross margin was affected by the unfavorable effects of higher commodity expenses and tariffs compared to the prior year, with productivity a modest offset in the quarter. Margins are expected to remain under pressure until the Company realizes the benefits expected from recently implemented pricing actions, productivity initiatives and other mitigating actions, which are expected to build as the fiscal year progresses. We continue to monitor macroeconomic trends and uncertainties such as consumer and economic uncertainty, key ingredient inflation, supply chain challenges, and the effects of tariffs, which may have adverse effects on net sales and profitability. We are

------

<u>[Table](#i49be39206c734f3a8b58002db19dcadf_7)[of Contents](#i49be39206c734f3a8b58002db19dcadf_7)</u>

continuing to evaluate these factors and our ability to potentially offset all or a portion of cost increases through pricing actions and cost savings efforts. Economic pressures on customers and consumers, including the challenges of high inflation and the effects of tariffs, may negatively affect our net sales and profitability in the future.

**Key Financial Definitions**

**Net sales.** Net sales consist primarily of product sales less the cost of promotional activities, slotting fees and other sales credits and adjustments, including product returns.

**Cost of goods sold.** Cost of goods sold consists primarily of the costs we pay to our contract manufacturing partners to produce the products sold. These costs include the purchase of raw ingredients, packaging, shipping and handling, warehousing, depreciation of warehouse equipment, and a tolling charge for the contract manufacturer. Cost of goods sold includes products provided at no charge as part of promotions and the non-food materials provided with customer orders.

**Operating expenses.** Operating expenses consist primarily of selling and marketing, general and administrative, depreciation and amortization, and business transaction costs. The following is a brief description of the components of operating expenses:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Selling and marketing.* Selling and marketing expenses are comprised of broker commissions, customer marketing, media and other marketing costs.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *General and administrative.* General and administrative expenses are comprised of expenses associated with corporate and administrative functions that support our business, including employee compensation, stock-based compensation, professional services, executive transition costs, integration expense, restructuring costs, insurance and other general corporate expenses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Depreciation and amortization.* Depreciation and amortization expenses consist of expenses associated with the depreciation of fixed assets and capitalized leasehold improvements and amortization of intangible assets.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;*• Business Transaction Costs.* Business transaction costs are comprised of transaction advisory fees, non-deferrable debt issuance costs, legal, due diligence, consulting, and accounting expenses associated with the OWYN Acquisition.

**Results of Operations**

During the thirteen weeks ended November 29, 2025, our net sales decreased 0.3% to $340.2 million compared to $341.3 million for the thirteen weeks ended November 30, 2024, driven by distribution-related declines for Atkins and modest declines for OWYN, which were partially offset by Quest volume-driven growth.

Gross profit decreased and gross profit margin decreased 590 basis points, primarily as a result of unfavorable commodity expenses and tariffs compared to the prior period. We expect to continue building on our existing capabilities and strengthening the position of our brands in the marketplace, and will continue to invest in our business and improve our operating efficiencies.

In assessing the performance of our business, we consider a number of key performance indicators used by management and typically used by our competitors, including the non-GAAP measures EBITDA and Adjusted EBITDA. Because not all companies use identical calculations, this presentation of EBITDA and Adjusted EBITDA may not be comparable to other similarly titled measures of other companies. See "*Reconciliation of EBITDA and Adjusted EBITDA*" below for a reconciliation of EBITDA and Adjusted EBITDA to net income for each applicable period.

------

<u>[**Table of Contents**](#i49be39206c734f3a8b58002db19dcadf_7)</u>

***Comparison of Unaudited Results for the Thirteen Weeks Ended November 29, 2025, and the Thirteen Weeks Ended November 30, 2024***

The following unaudited table presents, for the periods indicated, selected information from our Consolidated Statements of Operations and Comprehensive Income, including information presented as a percentage of net sales:

---

| | | | | |
|:---|:---|:---|:---|:---|
| | Thirteen Weeks Ended | | Thirteen Weeks Ended | |
| *(In thousands)* | November 29, 2025 | % of Net Sales | November 30, 2024 | % of Net Sales |
| Net sales | $340198 | 100.0% | $341268 | 100.0% |
| Cost of goods sold | 230298 | 67.7% | 210782 | 61.8% |
| Gross profit | 109900 | 32.3% | 130486 | 38.2% |
| Operating expenses: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Selling and marketing | 29677 | 8.7% | 32994 | 9.7% |
| &nbsp;&nbsp;&nbsp;&nbsp;General and administrative | 38006 | 11.2% | 38064 | 11.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | 4633 | 1.4% | 4160 | 1.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;Business transaction costs |  | —% | 643 | 0.2% |
| Total operating expenses | 72316 | 21.3% | 75861 | 22.2% |
| Income from operations | 37584 | 11.0% | 54625 | 16.0% |
| Other income (expense): |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest income | 499 | 0.1% | 776 | 0.2% |
| &nbsp;&nbsp;&nbsp;&nbsp;Interest expense | (4286) | (1.3)% | (7861) | (2.3)% |
| &nbsp;&nbsp;&nbsp;&nbsp;(Loss) gain on foreign currency transactions | (57) | —% | 120 | —% |
| &nbsp;&nbsp;&nbsp;&nbsp;Other income | 76 | —% | 15 | —% |
| Total other income (expense) | (3768) | (1.1)% | (6950) | (2.0)% |
| Income before income taxes | 33816 | 9.9% | 47675 | 14.0% |
| Income tax expense | 8547 | 2.5% | 9553 | 2.8% |
| Net income | $25269 | 7.4% | $38122 | 11.2% |
| Other financial data: |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Adjusted EBITDA <sup>(1)</sup> | $55624 | 16.4% | $70068 | 20.5% |
| <sup>(1)</sup> Adjusted EBITDA is a non-GAAP financial metric. See "Reconciliation of EBITDA and Adjusted EBITDA" below for a reconciliation of net income to EBITDA and Adjusted EBITDA for each applicable period. | <sup>(1)</sup> Adjusted EBITDA is a non-GAAP financial metric. See "Reconciliation of EBITDA and Adjusted EBITDA" below for a reconciliation of net income to EBITDA and Adjusted EBITDA for each applicable period. | <sup>(1)</sup> Adjusted EBITDA is a non-GAAP financial metric. See "Reconciliation of EBITDA and Adjusted EBITDA" below for a reconciliation of net income to EBITDA and Adjusted EBITDA for each applicable period. | <sup>(1)</sup> Adjusted EBITDA is a non-GAAP financial metric. See "Reconciliation of EBITDA and Adjusted EBITDA" below for a reconciliation of net income to EBITDA and Adjusted EBITDA for each applicable period. | <sup>(1)</sup> Adjusted EBITDA is a non-GAAP financial metric. See "Reconciliation of EBITDA and Adjusted EBITDA" below for a reconciliation of net income to EBITDA and Adjusted EBITDA for each applicable period. |

---

***Net sales***. Net sales were $340.2 million for the thirteen weeks ended November 29, 2025, compared to $341.3 million for the thirteen weeks ended November 30, 2024, representing an decrease of $1.1 million, or 0.3%, driven by distribution-related declines for Atkins and modest declines for OWYN, which were partially offset by Quest volume-driven growth.

***Cost of goods sold****.* Cost of goods sold increased $19.5 million, or 9.3%, for the thirteen weeks ended November 29, 2025, compared to the thirteen weeks ended November 30, 2024. The cost of goods sold increase was driven primarily by higher ingredient and packaging costs compared to the prior year period.

***Gross profit.*** Gross profit decreased $20.6 million, or 15.8%, to $109.9 million for the thirteen weeks ended November 29, 2025, compared to the thirteen weeks ended November 30, 2024. Gross profit margin was 32.3% of net sales for the thirteen weeks ended November 29, 2025, a decrease of 590 basis points from 38.2% of net sales for the thirteen weeks ended November 30, 2024. The decrease in gross profit margin was primarily driven by unfavorable commodity expenses compared to the prior year period and lower gross profit margins of the OWYN business.

***Operating expenses***. Operating expenses decreased $3.5 million, or 4.7%, for the thirteen weeks ended November 29, 2025, compared to the thirteen weeks ended November 30, 2024, due to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Selling and marketing.* Selling and marketing expenses decreased $3.3 million, or 10.1%, for the thirteen weeks ended November 29, 2025, compared to the thirteen weeks ended November 30, 2024. The decrease was primarily related to a planned decrease in Atkins marketing spend partially offset by increases for Quest and OWYN.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *General and administrative.* General and administrative expenses decreased $0.1 million, or 0.2%, for the thirteen weeks ended

------

<u>[**Table of Contents**](#i49be39206c734f3a8b58002db19dcadf_7)</u>

November 29, 2025, compared to the thirteen weeks ended November 30, 2024. The decrease was primarily attributable to a decrease of $1.7 million in integration expenses related to the OWYN Acquisition, a decrease of $0.8 million in stock based compensation, and a decrease of $0.2 million in employee-related costs, partially offset by an increase of $2.8 million in term loan transaction fees related to the 2026 Incremental Facility Amendment.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Depreciation and amortization.* Depreciation and amortization expense was $4.6 million for the thirteen weeks ended November 29, 2025, and $4.2 million for the thirteen weeks ended November 30, 2024, respectively.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• *Business transaction costs.* Business transaction costs were zero for the thirteen weeks ended November 29, 2025, compared to $0.6 million for the thirteen weeks ended November 30, 2024, and were comprised of expenses related to the OWYN Acquisition.

***Interest income.*** Interest income of $0.5 million decreased $0.3 million for the thirteen weeks ended November 29, 2025, compared to the thirteen weeks ended November 30, 2024.

***Interest expense****.* Interest expense of $4.3 million decreased $3.6 million for the thirteen weeks ended November 29, 2025, compared to the thirteen weeks ended November 30, 2024, primarily due to the effect of principal payments reducing the outstanding balance of the Term Facility (as defined below), prior to the incremental borrowing on November 19, 2025, which increased the outstanding balance to $400.0 million as of the thirteen weeks ended November 29, 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***(Loss) gain on foreign currency transactions.*** Foreign currency transactions resulted in a $0.1 million loss for the thirteen weeks ended November 29, 2025, and a $0.1 million gain for the thirteen weeks ended November 30, 2024.

***Income tax expense.*** Income tax expense was $8.5 million for the thirteen weeks ended November 29, 2025, compared to $9.6 million during the thirteen weeks ended November 30, 2024. The decrease in our income tax expense was primarily driven by a decrease in income before taxes.

***Net income***. Net income was $25.3 million for the thirteen weeks ended November 29, 2025, a decrease of $12.9 million, compared to net income of $38.1 million for the thirteen weeks ended November 30, 2024. Net income was affected by lower income from operations, partially offset by lower other expense and income tax expense.

***Adjusted EBITDA.*** Adjusted EBITDA decreased $14.4 million, or 20.6%, for the thirteen weeks ended November 29, 2025, compared to the thirteen weeks ended November 30, 2024, driven primarily by lower gross profit. For a reconciliation of Adjusted EBITDA to its most directly comparable GAAP measure, see "Reconciliation of EBITDA and Adjusted EBITDA" below.

------

<u>[**Table of Contents**](#i49be39206c734f3a8b58002db19dcadf_7)</u>

***Reconciliation of EBITDA and Adjusted EBITDA***

EBITDA and Adjusted EBITDA are non-GAAP financial measures commonly used in our industry and should not be construed as alternatives to net income as an indicator of operating performance or as alternatives to cash flow provided by operating activities as a measure of liquidity (each as determined in accordance with GAAP). The Company defines EBITDA as net income or loss before interest income, interest expense, income tax expense, depreciation and amortization, and Adjusted EBITDA as further adjusted to exclude the following items: stock-based compensation expense, business transaction costs, purchase price accounting inventory step-up, integration expenses, term loan transaction fees, and other non-core expenses. The Company believes that EBITDA and Adjusted EBITDA, when used in conjunction with net income, are useful to provide additional information to investors. Management of the Company uses EBITDA and Adjusted EBITDA to supplement net income because these measures reflect operating results of the on-going operations, eliminate items that are not directly attributable to the Company's underlying operating performance, enhance the overall understanding of past financial performance and future prospects, and allow for greater transparency with respect to the key metrics the Company's management uses in its financial and operational decision making. The Company also believes that EBITDA and Adjusted EBITDA are frequently used by securities analysts, investors and other interested parties in the evaluation of companies in its industry. EBITDA and Adjusted EBITDA may not be comparable to other similarly titled captions of other companies due to differences in the non-GAAP calculation.

The following unaudited table provides a reconciliation of EBITDA and Adjusted EBITDA to its most directly comparable GAAP measure, which is net income, for the thirteen weeks ended November 29, 2025, and November 30, 2024:

---

| | | |
|:---|:---|:---|
| *(In thousands)* | Thirteen Weeks Ended | Thirteen Weeks Ended |
| *(In thousands)* | November 29, 2025 | November 30, 2024 |
| Net income | $25269 | $38122 |
| Interest income | (499) | (776) |
| Interest expense | 4286 | 7861 |
| Income tax expense | 8547 | 9553 |
| Depreciation and amortization | 6205 | 5047 |
| EBITDA | 43808 | 59807 |
| &nbsp;&nbsp;&nbsp;Stock-based compensation expense | 3083 | 3844 |
| &nbsp;&nbsp;&nbsp;Business transaction costs |  | 643 |
| &nbsp;&nbsp;&nbsp;Inventory step-up |  | 974 |
| &nbsp;&nbsp;&nbsp;Integration expense | 5918 | 4931 |
| &nbsp;&nbsp;&nbsp;Term loan transaction fees | 2828 |  |
| &nbsp;&nbsp;Other <sup>(1)</sup> | (13) | (131) |
| Adjusted EBITDA | $55624 | $70068 |
| <sup>(1)</sup> Other items consist principally of exchange impact of foreign currency transactions and other expenses. | <sup>(1)</sup> Other items consist principally of exchange impact of foreign currency transactions and other expenses. | <sup>(1)</sup> Other items consist principally of exchange impact of foreign currency transactions and other expenses. |

---

------

<u>[**Table of Contents**](#i49be39206c734f3a8b58002db19dcadf_7)</u>

**Liquidity and Capital Resources**

***Overview***

We have historically funded our operations with cash flow from operations and, when needed, with borrowings under our Credit Agreement (as defined below). Our principal uses of cash have been working capital, debt service, repurchases of our common stock, and acquisition opportunities.

We had $194.1 million in cash as of November 29, 2025. We believe our sources of liquidity and capital will be sufficient to finance our continued operations, growth strategy and additional expenses we expect to incur for at least the next twelve months. As circumstances warrant, we may issue debt and/or equity securities from time to time on an opportunistic basis, dependent upon market conditions and available pricing. We make no assurance that we can issue and sell such securities on acceptable terms or at all.

Our material future cash requirements from contractual and other obligations relate primarily to our principal and interest payments for our Term Facility, as defined and discussed below, and our operating leases. Refer to Note 5, Long-Term Debt and Line of Credit, and Note 8, Leases, of the Notes to Unaudited Consolidated Financial Statements in this Report for additional information related to the expected timing and amount of payments related to our contractual and other obligations.

***Debt and Credit Facilities***

On July 7, 2017, the Company (through certain of its subsidiaries) entered into a credit agreement with Barclays Bank PLC and other parties (as amended to date, the "Credit Agreement"). The Credit Agreement at that time provided for (i) a term facility of $200.0 million ("Term Facility") with a seven-year maturity and (ii) a revolving credit facility of up to $75.0 million (the "Revolving Credit Facility") with a five-year maturity. Substantially concurrent with the consummation of the business combination which formed the Company between Conyers Park Acquisition Corp. and NCP-ATK Holdings, Inc. on July 7, 2017, the full $200.0 million of the Term Facility (the "Term Loan") was drawn.

On November 7, 2019, we entered into a second amendment (the "Incremental Facility Amendment") to the Credit Agreement to increase the principal borrowed on the Term Facility by $460.0 million. The Term Facility together with the incremental borrowing make up the Initial Term Loans (as defined in the Incremental Facility Amendment). The Incremental Facility Amendment was executed to partially finance the acquisition of Quest Nutrition, LLC on November 7, 2019. No amounts under the Term Facility were repaid as a result of the execution of the Incremental Facility Amendment.

Effective as of December 16, 2021, we entered into a third amendment (the "Extension Amendment") to the Credit Agreement. The Extension Amendment provided for an extension of the stated maturity date of the Revolving Commitments and Revolving Loans (each as defined in the Credit Agreement) from July 7, 2022, to the earlier of (i) 91 days prior to the then-effective maturity date of the Initial Term Loans and (ii) December 16, 2026.

On January 21, 2022, we entered into the "2022 Repricing Amendment" to the Credit Agreement. The 2022 Repricing Amendment, among other things, (i) reduced the interest rate per annum applicable to the Initial Term Loans outstanding under the Credit Agreement immediately prior to the effective date of the 2022 Repricing Amendment, (ii) reset the prepayment premium for the existing Initial Term Loans to apply to Repricing Transactions (as defined in the Credit Agreement) that occur within six months after the effective date of the 2022 Repricing Amendment, and (iii) implemented SOFR and related replacement provisions for LIBOR.

On April 25, 2023, the Company entered into the "2023 Repricing Amendment" to the Credit Agreement. The 2023 Repricing Amendment, (i) reduced the interest rate per annum applicable to the Initial Term Loans outstanding under the Credit Agreement immediately prior to April 25, 2023, and (ii) provided for an extension of the maturity date of the Initial Term Loans from July 7, 2024, to March 17, 2027.

On June 13, 2024, the Company entered into a sixth amendment (the "2024 Incremental Facility Amendment") to the Credit Agreement to increase the principal borrowed on the Term Facility by $250.0 million. The terms of the incremental borrowing are the same as the terms of the outstanding borrowings under the Term Facility. The 2024 Incremental Facility Amendment was executed to partially finance the OWYN Acquisition. No amounts under the Term Facility were repaid as a result of the execution of the 2024 Incremental Facility Amendment.

On January 31, 2025, the Company entered into a seventh amendment (the "2025 Repricing Amendment") to the Credit Agreement to reduce the interest rate per annum applicable to the Initial Term Loans outstanding under the Credit Agreement immediately prior to the effective date of the 2025 Repricing Amendment.

On November 19, 2025, the Company entered into an eighth amendment (the "2026 Incremental Facility Amendment") to the Credit Agreement to increase the principal borrowed on the Term Facility by $150.0 million and provided for an extension of the maturity date from March 17, 2027 to March 17, 2030. The 2026 Incremental Facility Amendment also provided for an extension of the stated maturity date of the Revolving Commitments and Revolving Loans (each as defined in the Credit Agreement) from December 16, 2026, to the earlier of (i) 91 days

------

<u>[**Table of Contents**](#i49be39206c734f3a8b58002db19dcadf_7)</u>

prior to the then-effective maturity date of the Term Facility and (ii) December 16, 2029. The terms of the incremental borrowing are substantially the same as the terms of the outstanding borrowings under the Term Facility. No amounts of the Term Facility were repaid as a result of the execution of the 2026 Incremental Facility Amendment.

Effective as of the 2026 Incremental Facility Amendment, the interest rate per annum for the Initial Term Loans is based on either:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;i.A base rate equaling the higher of (a) the "prime rate," (b) the federal funds effective rate plus 0.50%, or (c) the Adjusted Term SOFR Rate (as defined in the Credit Agreement) applicable for an interest period of one month plus 1.00% plus (x) 1.00% margin for the Term Loan or (y) 1.00% margin for the Revolving Credit Facility; or

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;ii.SOFR, subject to a floor of 0.00%, plus (x) 2.00% margin for the Term Loan or (y) 2.00% margin for the Revolving Credit Facility.

In connection with the closing of the 2026 Incremental Facility Amendment, the Company expensed $2.5 million of non-deferrable third-party costs through *General and administrative* within the Consolidated Statements of Operations and Comprehensive Income and capitalized $2.6 million of upfront lender fees (original issue discount) and third-party financing costs.

The Simply Good Foods Company is not a borrower under the Credit Agreement and has not provided a guarantee of the Credit Agreement. Simply Good Foods USA, Inc., is the administrative borrower and certain other subsidiary holding companies are co-borrowers under the Credit Agreement. Each of our domestic subsidiaries that is not a named borrower under the Credit Agreement has provided a guarantee on a secured basis. As security for the payment or performance of the debt under the Credit Agreement, the borrowers and the guarantors have pledged certain equity interests in their respective subsidiaries and granted the lenders a security interest in substantially all of their domestic assets. All guarantors other than Quest Nutrition, LLC and Only What You Need, Inc. are holding companies with no assets other than their investments in their respective subsidiaries.

The Credit Agreement contains certain financial and other covenants that limit our ability to, among other things, incur and/or undertake asset sales and other dispositions, liens, indebtedness, certain acquisitions and investments, consolidations, mergers, reorganizations and other fundamental changes, payment of dividends and other distributions to equity and warrant holders, and prepayments of material subordinated debt, in each case, subject to customary exceptions materially consistent with credit facilities of such type and size. The Revolving Credit Facility has a maximum total net leverage ratio equal to or less than 6.00:1.00 contingent on credit extensions in excess of 30% of the total amount of commitments available under the Revolving Credit Facility. Any failure to comply with the restrictions of the credit facilities may result in an event of default. We were in compliance with all covenants as of November 29, 2025, and August 30, 2025, respectively.

At November 29, 2025, the outstanding balance of the Term Facility was $400.0 million. We are not required to make principal payments on the Term Facility over the twelve months following the period ended November 29, 2025. The outstanding balance of the Term Facility is due upon its maturity in March 2030. As of November 29, 2025, there were no amounts drawn against the Revolving Credit Facility.

***Stock Repurchase Program***

On October 21, 2025, the Company's Board of Directors approved the addition of $150.0 million to our stock repurchase program, resulting in authorized stock repurchases of up to an aggregate amount of $300.0 million. During the thirteen weeks ended November 29, 2025, the Company repurchased 4,983,514 shares of common stock at an average price of $19.99 per share, inclusive of commissions exclusive of accrued excise tax. The U.S. Inflation Reduction Act of 2022 requires a 1% excise tax on the net amount of share repurchases. The Company did not repurchase any shares of common stock during the thirteen weeks ended November 30, 2024.

As of November 29, 2025, approximately $71.0 million remained available for repurchases under our $300.0 million stock repurchase program. Refer to Note 10, Stockholders' Equity, of the Notes to Unaudited Consolidated Financial Statements in this Report for additional information related to our stock repurchase program.

In January 2026, the Company's Board of Directors approved a $200 million increase to its existing stock repurchase program. Subsequent to the thirteen weeks ended November 29, 2025 and through January 6, 2026 the Company repurchased of 2,430,028 shares of common stock at an average price of $19.34 per share, inclusive of commissions and exclusive of accrued excise tax. As of January 6, 2026, the Company has approximately $224.0 million available under its revised stock repurchase program.

------

<u>[**Table of Contents**](#i49be39206c734f3a8b58002db19dcadf_7)</u>

***Cash Flows***

The following table sets forth the major sources and uses of cash for each of the periods set forth below (in thousands):

---

| | | |
|:---|:---|:---|
| | Thirteen Weeks Ended | Thirteen Weeks Ended |
| | November 29, 2025 | November 30, 2024 |
| Net cash provided by operating activities | $50094 | $32021 |
| Net cash used in investing activities | $(2096) | $(669) |
| Net cash provided by (used in) financing activities | $47619 | $(42331) |

---

*Operating activities.* Our net cash provided by operating activities increased $18.1 million to $50.1 million for the thirteen weeks ended November 29, 2025, compared to $32.0 million for the thirteen weeks ended November 30, 2024. The increase in cash provided by operating activities was primarily attributable to changes in working capital for the thirteen weeks ended November 29, 2025, as compared to the thirteen weeks ended November 30, 2024. Changes in working capital, comprised of changes in accounts receivable, net, inventories, prepaid expenses, other current assets, accounts payable, accrued interest, accrued expenses and other current liabilities, and other assets and liabilities, were driven by the timing of payments and receipts, which provided cash of $10.6 million in the thirteen weeks ended November 29, 2025, compared to $20.8 million of cash used in the thirteen weeks ended November 30, 2024, a difference of $31.4 million. Income from operations decreased by $17.0 million to $37.6 million for the thirteen weeks ended November 29, 2025, as compared to $54.6 million for the thirteen weeks ended November 30, 2024. Additionally, cash paid for interest was $4.1 million in the thirteen weeks ended November 29, 2025, which was a decrease of $3.4 million as compared to the $7.5 million paid for interest in the thirteen weeks ended November 30, 2024.

*Investing activities*. Our net cash used in investing activities was $2.1 million for the thirteen weeks ended November 29, 2025, compared to $0.7 million for the thirteen weeks ended November 30, 2024. Our net cash used in investing activities for the thirteen weeks ended November 29, 2025, was primarily comprised of $2.1 million of purchases of property and equipment. The $0.7 million of net cash used in investing activities for the thirteen weeks ended November 30, 2024, was primarily comprised of $0.3 million of purchases of property and equipment and $0.4 million of investments in intangible and other assets.

*Financing activities*. Our net cash provided by financing activities was $47.6 million for the thirteen weeks ended November 29, 2025, compared to $42.3 million of cash used in financing activities for the thirteen weeks ended November 30, 2024. Net cash provided by financing activities for the thirteen weeks ended November 29, 2025, primarily consisted of $150.0 million in proceeds from issuance of long-term debt and $1.1 million of cash proceeds received from option exercises, partially offset by $99.6 million in repurchases of common stock, inclusive of commissions and exclusive of accrued excise tax, and $1.2 million in tax payments related to the issuance of restricted stock units and performance stock units. Net cash used in financing activities for the thirteen weeks ended November 30, 2024, primarily consisted of $50.0 million in principal payments on the Term Facility, and $2.3 million in tax payments related to issuance of restricted stock units and performance stock units, partially offset by $10.0 million of cash proceeds received from option exercises.

**New Accounting Pronouncements**

For a description of critical accounting policies that affect our significant judgments and estimates used in the preparation of our consolidated financial statements, refer to our Annual Report. Refer to Note 2, Summary of Significant Accounting Policies, of our unaudited interim consolidated financial statements in this Report for further information regarding recently issued accounting standards.

------

<u>[**Table of Contents**](#i49be39206c734f3a8b58002db19dcadf_7)</u>

**Item 3.&nbsp;&nbsp;&nbsp;&nbsp;Quantitative and Qualitative Disclosures about Market Risk** 

There were no material changes in our market risk exposure during the thirteen-week period ended November 29, 2025. For a discussion of our market risks, see "Quantitative and Qualitative Disclosures About Market Risk" in Part II, Item 7A of our Annual Report.

**Item 4.&nbsp;&nbsp;&nbsp;&nbsp;Controls and Procedures**

We maintain disclosure controls and procedures, as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), that are designed to provide reasonable assurance that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required financial disclosures.

Management, including the participation of our Chief Executive Officer and our Chief Financial Officer, conducted an evaluation (pursuant to Rule 13a-15(b) under the Exchange Act) of the effectiveness of our disclosure controls and procedures as of the end of the period covered by this Report. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded that, as of November 29, 2025, the Company's disclosure controls and procedures were effective.

**Changes in Internal Control over Financial Reporting**

There were no changes in our internal control over financial reporting during the quarter ended November 29, 2025, that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.&nbsp;&nbsp;&nbsp;&nbsp;

**Inherent Limitations on Effectiveness of Controls** 

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. All internal control systems, no matter how well designed, have inherent limitations. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Additionally, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

------

<u>[Table](#i49be39206c734f3a8b58002db19dcadf_7)[of Contents](#i49be39206c734f3a8b58002db19dcadf_7)</u>

**PART II. Other Information**

**Item 1.&nbsp;&nbsp;&nbsp;&nbsp;Legal Proceedings**

From time to time, we have been and may again become involved in legal proceedings arising in the ordinary course of our business. We are not presently a party to any litigation that we believe to be material and we are not aware of any pending or threatened litigation against us that we believe could have a material adverse effect on our business, operating results, financial condition or cash flows.

**Item 1A. Risk Factors**

Readers should carefully consider the factors discussed in Part I, Item 1A. "Risk Factors" in our Annual Report, which could materially affect our business, financial condition, cash flows or future results. There have been no material changes in our risk factors included in our Annual Report. The risks described in our Annual Report are not the only risks facing our Company. Additional risks and uncertainties not currently known to us or that we currently deem to be immaterial may also materially adversely affect our business, financial condition or future results.

------

<u>[Table](#i49be39206c734f3a8b58002db19dcadf_7)[of Contents](#i49be39206c734f3a8b58002db19dcadf_7)</u>

**Item 2.&nbsp;&nbsp;&nbsp;&nbsp;Unregistered Sales of Equity Securities and Use of Proceeds**

Issuer Purchases of Equity Securities

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| Period | Total number of shares purchased | Average price paid per share<sup>(2)</sup> | Average price paid per share<sup>(2)</sup> | Total number of shares purchased as part of publicly announced plans or programs<sup>(1)</sup> | Maximum dollar value of shares that may yet be purchased under the plans or programs<sup>(1)</sup> | Maximum dollar value of shares that may yet be purchased under the plans or programs<sup>(1)</sup> |
| August 31, 2025 - September 27, 2025 |  | $|  |  | $| 20661295 |
| September 28, 2025 - October 25, 2025 |  |  |  |  | 20661295 | 20661295 |
| October 26, 2025 - November 29, 2025 | 4983514 | 19.99 | 19.99 | 4983514 | 71023559 | 71023559 |
| Total | 4983514 | $| 19.99 | 4983514 | $| 71023559 |
| <sup>(1)</sup> We adopted a $50.0 million stock repurchase program on November 13, 2018. On April 13, 2022, October 21, 2022, and October 21, 2025, we announced that our Board of Directors had approved the addition of $50.0 million, $50.0 million, and $150.0 million, respectively, to our stock repurchase program, resulting in authorized stock repurchases of up to an aggregate of $300.0 million. As of November 29, 2025, approximately $71.0 million remained available under the stock repurchase program. In January 2026, the Company's Board of Directors approved a $200 million increase to its existing stock repurchase program. Subsequent to the thirteen weeks ended November 29, 2025 and through January 6, 2026 the Company repurchased 2,430,028 shares of common stock at an average price of $19.34 per share, inclusive of commissions and exclusive of accrued excise tax. As of January 6, 2026, the Company has approximately $224.0 million available under its revised stock repurchase program. Under the stock repurchase program, we may repurchase shares from time to time in the open market or in privately negotiated transactions. The stock repurchase program does not obligate us to acquire any specific number of shares over any specific period of time. We may suspend or discontinue the stock repurchase program at any time, and the stock repurchase program does not have an expiration date. | <sup>(1)</sup> We adopted a $50.0 million stock repurchase program on November 13, 2018. On April 13, 2022, October 21, 2022, and October 21, 2025, we announced that our Board of Directors had approved the addition of $50.0 million, $50.0 million, and $150.0 million, respectively, to our stock repurchase program, resulting in authorized stock repurchases of up to an aggregate of $300.0 million. As of November 29, 2025, approximately $71.0 million remained available under the stock repurchase program. In January 2026, the Company's Board of Directors approved a $200 million increase to its existing stock repurchase program. Subsequent to the thirteen weeks ended November 29, 2025 and through January 6, 2026 the Company repurchased 2,430,028 shares of common stock at an average price of $19.34 per share, inclusive of commissions and exclusive of accrued excise tax. As of January 6, 2026, the Company has approximately $224.0 million available under its revised stock repurchase program. Under the stock repurchase program, we may repurchase shares from time to time in the open market or in privately negotiated transactions. The stock repurchase program does not obligate us to acquire any specific number of shares over any specific period of time. We may suspend or discontinue the stock repurchase program at any time, and the stock repurchase program does not have an expiration date. | <sup>(1)</sup> We adopted a $50.0 million stock repurchase program on November 13, 2018. On April 13, 2022, October 21, 2022, and October 21, 2025, we announced that our Board of Directors had approved the addition of $50.0 million, $50.0 million, and $150.0 million, respectively, to our stock repurchase program, resulting in authorized stock repurchases of up to an aggregate of $300.0 million. As of November 29, 2025, approximately $71.0 million remained available under the stock repurchase program. In January 2026, the Company's Board of Directors approved a $200 million increase to its existing stock repurchase program. Subsequent to the thirteen weeks ended November 29, 2025 and through January 6, 2026 the Company repurchased 2,430,028 shares of common stock at an average price of $19.34 per share, inclusive of commissions and exclusive of accrued excise tax. As of January 6, 2026, the Company has approximately $224.0 million available under its revised stock repurchase program. Under the stock repurchase program, we may repurchase shares from time to time in the open market or in privately negotiated transactions. The stock repurchase program does not obligate us to acquire any specific number of shares over any specific period of time. We may suspend or discontinue the stock repurchase program at any time, and the stock repurchase program does not have an expiration date. | <sup>(1)</sup> We adopted a $50.0 million stock repurchase program on November 13, 2018. On April 13, 2022, October 21, 2022, and October 21, 2025, we announced that our Board of Directors had approved the addition of $50.0 million, $50.0 million, and $150.0 million, respectively, to our stock repurchase program, resulting in authorized stock repurchases of up to an aggregate of $300.0 million. As of November 29, 2025, approximately $71.0 million remained available under the stock repurchase program. In January 2026, the Company's Board of Directors approved a $200 million increase to its existing stock repurchase program. Subsequent to the thirteen weeks ended November 29, 2025 and through January 6, 2026 the Company repurchased 2,430,028 shares of common stock at an average price of $19.34 per share, inclusive of commissions and exclusive of accrued excise tax. As of January 6, 2026, the Company has approximately $224.0 million available under its revised stock repurchase program. Under the stock repurchase program, we may repurchase shares from time to time in the open market or in privately negotiated transactions. The stock repurchase program does not obligate us to acquire any specific number of shares over any specific period of time. We may suspend or discontinue the stock repurchase program at any time, and the stock repurchase program does not have an expiration date. | <sup>(1)</sup> We adopted a $50.0 million stock repurchase program on November 13, 2018. On April 13, 2022, October 21, 2022, and October 21, 2025, we announced that our Board of Directors had approved the addition of $50.0 million, $50.0 million, and $150.0 million, respectively, to our stock repurchase program, resulting in authorized stock repurchases of up to an aggregate of $300.0 million. As of November 29, 2025, approximately $71.0 million remained available under the stock repurchase program. In January 2026, the Company's Board of Directors approved a $200 million increase to its existing stock repurchase program. Subsequent to the thirteen weeks ended November 29, 2025 and through January 6, 2026 the Company repurchased 2,430,028 shares of common stock at an average price of $19.34 per share, inclusive of commissions and exclusive of accrued excise tax. As of January 6, 2026, the Company has approximately $224.0 million available under its revised stock repurchase program. Under the stock repurchase program, we may repurchase shares from time to time in the open market or in privately negotiated transactions. The stock repurchase program does not obligate us to acquire any specific number of shares over any specific period of time. We may suspend or discontinue the stock repurchase program at any time, and the stock repurchase program does not have an expiration date. | <sup>(1)</sup> We adopted a $50.0 million stock repurchase program on November 13, 2018. On April 13, 2022, October 21, 2022, and October 21, 2025, we announced that our Board of Directors had approved the addition of $50.0 million, $50.0 million, and $150.0 million, respectively, to our stock repurchase program, resulting in authorized stock repurchases of up to an aggregate of $300.0 million. As of November 29, 2025, approximately $71.0 million remained available under the stock repurchase program. In January 2026, the Company's Board of Directors approved a $200 million increase to its existing stock repurchase program. Subsequent to the thirteen weeks ended November 29, 2025 and through January 6, 2026 the Company repurchased 2,430,028 shares of common stock at an average price of $19.34 per share, inclusive of commissions and exclusive of accrued excise tax. As of January 6, 2026, the Company has approximately $224.0 million available under its revised stock repurchase program. Under the stock repurchase program, we may repurchase shares from time to time in the open market or in privately negotiated transactions. The stock repurchase program does not obligate us to acquire any specific number of shares over any specific period of time. We may suspend or discontinue the stock repurchase program at any time, and the stock repurchase program does not have an expiration date. | <sup>(1)</sup> We adopted a $50.0 million stock repurchase program on November 13, 2018. On April 13, 2022, October 21, 2022, and October 21, 2025, we announced that our Board of Directors had approved the addition of $50.0 million, $50.0 million, and $150.0 million, respectively, to our stock repurchase program, resulting in authorized stock repurchases of up to an aggregate of $300.0 million. As of November 29, 2025, approximately $71.0 million remained available under the stock repurchase program. In January 2026, the Company's Board of Directors approved a $200 million increase to its existing stock repurchase program. Subsequent to the thirteen weeks ended November 29, 2025 and through January 6, 2026 the Company repurchased 2,430,028 shares of common stock at an average price of $19.34 per share, inclusive of commissions and exclusive of accrued excise tax. As of January 6, 2026, the Company has approximately $224.0 million available under its revised stock repurchase program. Under the stock repurchase program, we may repurchase shares from time to time in the open market or in privately negotiated transactions. The stock repurchase program does not obligate us to acquire any specific number of shares over any specific period of time. We may suspend or discontinue the stock repurchase program at any time, and the stock repurchase program does not have an expiration date. |
| <sup>(2)</sup> Average price paid per share includes commissions, but excludes our liability under the 1% excise tax on the net amount of share repurchases required by the Inflation Reduction Act of 2022. | <sup>(2)</sup> Average price paid per share includes commissions, but excludes our liability under the 1% excise tax on the net amount of share repurchases required by the Inflation Reduction Act of 2022. | <sup>(2)</sup> Average price paid per share includes commissions, but excludes our liability under the 1% excise tax on the net amount of share repurchases required by the Inflation Reduction Act of 2022. | <sup>(2)</sup> Average price paid per share includes commissions, but excludes our liability under the 1% excise tax on the net amount of share repurchases required by the Inflation Reduction Act of 2022. | <sup>(2)</sup> Average price paid per share includes commissions, but excludes our liability under the 1% excise tax on the net amount of share repurchases required by the Inflation Reduction Act of 2022. | <sup>(2)</sup> Average price paid per share includes commissions, but excludes our liability under the 1% excise tax on the net amount of share repurchases required by the Inflation Reduction Act of 2022. | <sup>(2)</sup> Average price paid per share includes commissions, but excludes our liability under the 1% excise tax on the net amount of share repurchases required by the Inflation Reduction Act of 2022. |

---

------

<u>[Table](#i49be39206c734f3a8b58002db19dcadf_7)[of Contents](#i49be39206c734f3a8b58002db19dcadf_7)</u>

**Item 3.&nbsp;&nbsp;&nbsp;&nbsp;Defaults Upon Senior Securities**

None.

**Item 4.&nbsp;&nbsp;&nbsp;&nbsp;Mine Safety Disclosures**

Not Applicable.

**Item 5.&nbsp;&nbsp;&nbsp;&nbsp;Other Information**

In the three months ended November 29, 2025, no directors or officers adopted or terminated a "Rule 10b5-1 trading arrangement" or a "non-Rule 10b5-1 trading arrangement," as each term is defined in Item 408(a) of Regulation S-K.

------

<u>[**Table of Contents**](#i49be39206c734f3a8b58002db19dcadf_7)</u>

**Item 6.&nbsp;&nbsp;&nbsp;&nbsp;Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Document** |
| <u>[10.1](https://www.sec.gov/Archives/edgar/data/1702744/000110465925114309/tm2531697d1_ex10-1.htm)</u> | <u>[Amendment No. 8, dated as of November 19, 2025, among Atkins Intermediate Holdings, LLC, a Delaware limited liability company, Conyers Park Acquisition Corp., a Delaware corporation, Simply Good Foods USA, Inc., a New York corporation, Atkins Nutritionals Holdings, Inc., a Delaware corporation, Atkins Nutritionals Holdings II, Inc., a Delaware corporation, NCP-ATK Holdings, Inc., a Delaware corporation, certain other subsidiaries of Simply Good Foods USA, Inc., the lenders party thereto and Barclays Bank PLC, as administrative agent (incorporated by reference to Exhibit 10.1 to our Form 8-K filed on November 20, 2025).](https://www.sec.gov/Archives/edgar/data/1702744/000110465925114309/tm2531697d1_ex10-1.htm)</u> |
| <u>[31.1](exhibit311-q126.htm)</u>\* | <u>[Certification of Principal Executive Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002.](exhibit311-q126.htm)</u> |
| <u>[31.2](exhibit312-q126.htm)</u>\* | <u>[Certification of Principal Financial Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002.](exhibit312-q126.htm)</u> |
| <u>[32.1](exhibit321-q126.htm)</u>\*\* | <u>[Certification of Principal Executive Officer and Principal Financial Officer pursuant to Section 906 of the Sarbanes Oxley Act.](exhibit321-q126.htm)</u> |
| 101.INS\* | XBRL Instance Document (the instance document does not appear on the Interactive Data File because the XBRL tags are embedded within the Inline XBRL document) |
| 101.SCH\* | XBRL Taxonomy Extension Schema Document |
| 101.CAL\* | XBRL Taxonomy Extension Calculation Linkbase Document |
| 101.DEF\* | XBRL Taxonomy Extension Definition Linkbase Document |
| 101.LAB\* | XBRL Taxonomy Extension Label Linkbase Document |
| 101.PRE\* | XBRL Taxonomy Extension Presentation Linkbase Document |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document and contained in Exhibit 101). |
| \* Filed herewith. | \* Filed herewith. |
| \*\* Furnished herewith. | \*\* Furnished herewith. |

---

------

<u>[**Table of Contents**](#i49be39206c734f3a8b58002db19dcadf_7)</u>

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| | | By: | **THE SIMPLY GOOD FOODS COMPANY**<br>/s/ Timothy A. Matthews |
| Date: | January 8, 2026 | Name: | Timothy A. Matthews |
|  |  | Title: | Vice President, Controller, and Chief Accounting Officer |
|  |  |  | *(Duly Authorized Officer and Principal Accounting Officer)* |

---

## Exhibit 31.1

**Exhibit 31.1**

**CERTIFICATION**

**PURSUANT TO RULES 13a-14(a) AND 15d-14(a)**

**OF THE U.S. SECURITIES EXCHANGE ACT OF 1934**

**(Section 302 of the Sarbanes-Oxley Act of 2002)**

I, Geoff E. Tanner, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this Quarterly Report on Form 10-Q of The Simply Good Foods Company (the "registrant");

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)&nbsp;&nbsp;&nbsp;&nbsp; designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)&nbsp;&nbsp;&nbsp;&nbsp; designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)&nbsp;&nbsp;&nbsp;&nbsp; evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)&nbsp;&nbsp;&nbsp;&nbsp; disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)&nbsp;&nbsp;&nbsp;&nbsp; all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)&nbsp;&nbsp;&nbsp;&nbsp; any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | | |
|:---|:---|:---|:---|
| Date: | January 8, 2026 | By: | /s/ Geoff E. Tanner |
|  |  | Name: | Geoff E. Tanner |
|  |  | Title: | Chief Executive Officer, President and Director |
|  |  |  | *(Principal Executive Officer)* |

---

## Exhibit 31.2

**Exhibit 31.2**

**CERTIFICATION**

**PURSUANT TO RULES 13a-14(a) AND 15d-14(a)**

**OF THE U.S. SECURITIES EXCHANGE ACT OF 1934**

**(Section 302 of the Sarbanes-Oxley Act of 2002)**

I, Christopher Bealer, certify that:

&nbsp;&nbsp;&nbsp;&nbsp;1. I have reviewed this Quarterly Report on Form 10-Q of The Simply Good Foods Company (the "registrant");

&nbsp;&nbsp;&nbsp;&nbsp;2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

&nbsp;&nbsp;&nbsp;&nbsp;3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

&nbsp;&nbsp;&nbsp;&nbsp;4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)&nbsp;&nbsp;&nbsp;&nbsp; designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)&nbsp;&nbsp;&nbsp;&nbsp; designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;c)&nbsp;&nbsp;&nbsp;&nbsp; evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;d)&nbsp;&nbsp;&nbsp;&nbsp; disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

&nbsp;&nbsp;&nbsp;&nbsp;5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;a)&nbsp;&nbsp;&nbsp;&nbsp; all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;b)&nbsp;&nbsp;&nbsp;&nbsp; any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

---

| | | | |
|:---|:---|:---|:---|
| Date: | January 8, 2026 | By: | /s/ Christopher J. Bealer |
|  |  | Name: | Christopher J. Bealer |
|  |  | Title: | Chief Financial Officer |
|  |  |  | *(Principal Financial Officer)* |

---

## Exhibit 32.1

**Exhibit 32.1**

**CERTIFICATION**

**PURSUANT TO 18 U.S.C. SECTION 1350**

**AS ADOPTED PURSUANT TO**

**(SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002)**

&nbsp;&nbsp;&nbsp;&nbsp;In connection with the Quarterly Report of The Simply Good Foods Company (the "Company") on Form 10-Q for the fiscal period ended November 29, 2025, as filed with the Securities and Exchange Commission on the date hereof (the "Report"), each of the undersigned officers of the Company hereby certifies, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to such officer's knowledge:

&nbsp;&nbsp;&nbsp;&nbsp;1. The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and

&nbsp;&nbsp;&nbsp;&nbsp;2. The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company covered by the Report.

&nbsp;&nbsp;&nbsp;&nbsp;This certificate is being furnished solely for the purposes of 18 U.S.C. Section 1350 and is not being filed as part of the Report or as a separate disclosure document.

---

| | | | |
|:---|:---|:---|:---|
| Date: | January 8, 2026 | By: | /s/ Geoff E. Tanner |
|  |  | Name: | Geoff E. Tanner |
|  |  | Title: | Chief Executive Officer, President and Director |
|  |  |  | *(Principal Executive Officer)* |
| Date: | January 8, 2026 | By: | /s/ Christopher J. Bealer |
|  |  | Name: | Christopher J. Bealer |
|  |  | Title: | Chief Financial Officer |
|  |  |  | *(Principal Financial Officer)* |

---

<br>